PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers

Multidrug resistance (MDR) is the dominant challenge in the failure of chemotherapy in cancers. Phosphatidylinositol 3-kinase (PI3K) is a lipid kinase that spreads intracellular signal cascades and regulates a variety of cellular processes. PI3Ks are considered significant causes of chemoresistance...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Cell death & disease Ročník 11; číslo 9; s. 797
Hlavní autori:	Liu, Rui, Chen, Youwen, Liu, Guangzhi, Li, Chenxi, Song, Yurong, Cao, Zhiwen, Li, Wen, Hu, Jinghong, Lu, Cheng, Liu, Yuanyan
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	London Nature Publishing Group UK 24.09.2020
Predmet:	631/67/1059/602 631/67/2327 Antibodies Biochemistry Biomedical and Life Sciences Cell Biology Cell Culture Cell Proliferation Drug Resistance, Multiple - genetics Humans Immunology Life Sciences Neoplasms - drug therapy Neoplasms - genetics Proto-Oncogene Proteins c-akt - metabolism Review Review Article Signal Transduction
ISSN:	2041-4889, 2041-4889
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Abstract	Multidrug resistance (MDR) is the dominant challenge in the failure of chemotherapy in cancers. Phosphatidylinositol 3-kinase (PI3K) is a lipid kinase that spreads intracellular signal cascades and regulates a variety of cellular processes. PI3Ks are considered significant causes of chemoresistance in cancer therapy. Protein kinase B (AKT) is also a significant downstream effecter of PI3K signaling, and it modulates several pathways, including inhibition of apoptosis, stimulation of cell growth, and modulation of cellular metabolism. This review highlights the aberrant activation of PI3K/AKT as a key link that modulates MDR. We summarize the regulation of numerous major targets correlated with the PI3K/AKT pathway, which is further related to MDR, including the expression of apoptosis-related protein, ABC transport and glycogen synthase kinase-3 beta (GSK-3β), synergism with nuclear factor kappa beta (NF-κB) and mammalian target of rapamycin (mTOR), and the regulation of glycolysis.
AbstractList	Multidrug resistance (MDR) is the dominant challenge in the failure of chemotherapy in cancers. Phosphatidylinositol 3-kinase (PI3K) is a lipid kinase that spreads intracellular signal cascades and regulates a variety of cellular processes. PI3Ks are considered significant causes of chemoresistance in cancer therapy. Protein kinase B (AKT) is also a significant downstream effecter of PI3K signaling, and it modulates several pathways, including inhibition of apoptosis, stimulation of cell growth, and modulation of cellular metabolism. This review highlights the aberrant activation of PI3K/AKT as a key link that modulates MDR. We summarize the regulation of numerous major targets correlated with the PI3K/AKT pathway, which is further related to MDR, including the expression of apoptosis-related protein, ABC transport and glycogen synthase kinase-3 beta (GSK-3β), synergism with nuclear factor kappa beta (NF-κB) and mammalian target of rapamycin (mTOR), and the regulation of glycolysis. Multidrug resistance (MDR) is the dominant challenge in the failure of chemotherapy in cancers. Phosphatidylinositol 3-kinase (PI3K) is a lipid kinase that spreads intracellular signal cascades and regulates a variety of cellular processes. PI3Ks are considered significant causes of chemoresistance in cancer therapy. Protein kinase B (AKT) is also a significant downstream effecter of PI3K signaling, and it modulates several pathways, including inhibition of apoptosis, stimulation of cell growth, and modulation of cellular metabolism. This review highlights the aberrant activation of PI3K/AKT as a key link that modulates MDR. We summarize the regulation of numerous major targets correlated with the PI3K/AKT pathway, which is further related to MDR, including the expression of apoptosis-related protein, ABC transport and glycogen synthase kinase-3 beta (GSK-3β), synergism with nuclear factor kappa beta (NF-κB) and mammalian target of rapamycin (mTOR), and the regulation of glycolysis.Multidrug resistance (MDR) is the dominant challenge in the failure of chemotherapy in cancers. Phosphatidylinositol 3-kinase (PI3K) is a lipid kinase that spreads intracellular signal cascades and regulates a variety of cellular processes. PI3Ks are considered significant causes of chemoresistance in cancer therapy. Protein kinase B (AKT) is also a significant downstream effecter of PI3K signaling, and it modulates several pathways, including inhibition of apoptosis, stimulation of cell growth, and modulation of cellular metabolism. This review highlights the aberrant activation of PI3K/AKT as a key link that modulates MDR. We summarize the regulation of numerous major targets correlated with the PI3K/AKT pathway, which is further related to MDR, including the expression of apoptosis-related protein, ABC transport and glycogen synthase kinase-3 beta (GSK-3β), synergism with nuclear factor kappa beta (NF-κB) and mammalian target of rapamycin (mTOR), and the regulation of glycolysis.
ArticleNumber	797
Author	Liu, Rui Song, Yurong Liu, Yuanyan Lu, Cheng Chen, Youwen Li, Chenxi Hu, Jinghong Liu, Guangzhi Li, Wen Cao, Zhiwen
Author_xml	– sequence: 1 givenname: Rui surname: Liu fullname: Liu, Rui organization: School of Chinese Materia Medica, Beijing University of Chinese Medicine – sequence: 2 givenname: Youwen surname: Chen fullname: Chen, Youwen organization: School of Chinese Materia Medica, Beijing University of Chinese Medicine – sequence: 3 givenname: Guangzhi surname: Liu fullname: Liu, Guangzhi organization: School of Chinese Materia Medica, Beijing University of Chinese Medicine – sequence: 4 givenname: Chenxi surname: Li fullname: Li, Chenxi organization: School of Chinese Materia Medica, Beijing University of Chinese Medicine – sequence: 5 givenname: Yurong surname: Song fullname: Song, Yurong organization: School of Chinese Materia Medica, Beijing University of Chinese Medicine – sequence: 6 givenname: Zhiwen surname: Cao fullname: Cao, Zhiwen organization: School of Chinese Materia Medica, Beijing University of Chinese Medicine – sequence: 7 givenname: Wen surname: Li fullname: Li, Wen organization: School of Chinese Materia Medica, Beijing University of Chinese Medicine – sequence: 8 givenname: Jinghong surname: Hu fullname: Hu, Jinghong email: hujhbj@163.com organization: School of Chinese Materia Medica, Beijing University of Chinese Medicine – sequence: 9 givenname: Cheng surname: Lu fullname: Lu, Cheng email: lv_cheng0816@163.com organization: Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences – sequence: 10 givenname: Yuanyan surname: Liu fullname: Liu, Yuanyan email: yyliu_1980@163.com organization: School of Chinese Materia Medica, Beijing University of Chinese Medicine
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/32973135$$D View this record in MEDLINE/PubMed
BookMark	eNp9UUtPJCEQJhuNj9E_sIcNRy-tPBoaLpsYs6vGSfSgZ0LT9AzaDSPQbubfL-OocfcgSYWq1PdI6jsEOz54C8B3jE4xouIs1bjGskIElZJSVPwbOCCoxlUthNz51O-D45QeUXmUIsL4HtinRDYUU3YA5nfX9Obs_OYernRe_tFrqBPU8Mmu4eD8ExxDNw062wTz0sJxGrLr4rSA0SaXsvbGwtBDs2liOgK7vR6SPX77Z-Dh96_7i6tqfnt5fXE-rwzDJFeGYkx1ixrJesJZ34lGatRZo1vKJae1rVGDW9l2ZTDYCMspJayjRiPCW0xn4OdWdzW1o-2M9TnqQa2iG3Vcq6Cd-nfj3VItwotqGGaCsyJw8iYQw_NkU1ajS8YOg_Y2TEmRuuacC1z8Z-DHZ68Pk_cTFoDYAkwMKUXbK-Oyzi5srN2gMFKbwNQ2MFUCU6-BqY02-Y_6rv4liW5JqYD9wkb1GKboy72_Yv0FCqmnlw
CitedBy_id	crossref_primary_10_1016_j_jprot_2022_104539 crossref_primary_10_1016_j_ejphar_2023_176013 crossref_primary_10_1136_jitc_2024_008923 crossref_primary_10_1111_cas_16419 crossref_primary_10_1007_s12672_025_01829_4 crossref_primary_10_3389_fcell_2024_1372330 crossref_primary_10_3390_cancers14092255 crossref_primary_10_3389_fcell_2025_1584630 crossref_primary_10_3390_cancers13133351 crossref_primary_10_1152_ajpcell_00412_2025 crossref_primary_10_3390_life11121304 crossref_primary_10_3390_cells12050757 crossref_primary_10_3390_ijms242115525 crossref_primary_10_1186_s12967_023_04403_0 crossref_primary_10_3389_fmolb_2023_1116398 crossref_primary_10_2147_DDDT_S473678 crossref_primary_10_1007_s11064_024_04103_1 crossref_primary_10_1186_s13045_021_01129_8 crossref_primary_10_1016_j_tranon_2021_101208 crossref_primary_10_3389_fcell_2025_1639772 crossref_primary_10_3390_cancers17061008 crossref_primary_10_1007_s13402_022_00690_9 crossref_primary_10_1186_s12951_022_01626_z crossref_primary_10_1016_j_cellsig_2024_111434 crossref_primary_10_1186_s13048_025_01770_8 crossref_primary_10_1038_s41392_025_02167_1 crossref_primary_10_1515_oncologie_2023_0214 crossref_primary_10_1111_cpr_13448 crossref_primary_10_1002_ddr_21904 crossref_primary_10_1016_j_tranon_2024_102166 crossref_primary_10_3389_fonc_2023_1132424 crossref_primary_10_1016_j_jep_2024_118128 crossref_primary_10_3389_fimmu_2022_861221 crossref_primary_10_3389_fmars_2022_1017445 crossref_primary_10_1016_j_biopha_2024_117119 crossref_primary_10_1016_j_biopha_2022_113474 crossref_primary_10_3390_genes14061276 crossref_primary_10_3390_molecules26134100 crossref_primary_10_1002_iub_70042 crossref_primary_10_1016_j_mce_2021_111550 crossref_primary_10_3389_fgene_2022_906326 crossref_primary_10_1016_j_heliyon_2024_e32243 crossref_primary_10_1002_1878_0261_13741 crossref_primary_10_3389_fphar_2024_1345281 crossref_primary_10_1016_j_cbi_2024_111055 crossref_primary_10_1080_15384101_2025_2539643 crossref_primary_10_1186_s13020_025_01061_w crossref_primary_10_1007_s10495_022_01721_4 crossref_primary_10_1038_s41401_024_01312_w crossref_primary_10_1097_CAD_0000000000001612 crossref_primary_10_3389_fbioe_2021_799806 crossref_primary_10_1039_D5MA00161G crossref_primary_10_3389_fcell_2021_730538 crossref_primary_10_3389_fonc_2022_873649 crossref_primary_10_3389_fphar_2025_1653702 crossref_primary_10_3390_cells11203302 crossref_primary_10_1155_2022_3729069 crossref_primary_10_1007_s00210_025_04036_8 crossref_primary_10_1002_jbio_202400071 crossref_primary_10_1186_s12890_025_03509_z crossref_primary_10_1038_s41698_024_00714_7 crossref_primary_10_3390_foods14183278 crossref_primary_10_1016_j_micres_2024_127927 crossref_primary_10_1002_iub_2773 crossref_primary_10_2147_JIR_S545499 crossref_primary_10_3390_molecules29071570 crossref_primary_10_1002_gcc_70069 crossref_primary_10_1186_s12943_023_01787_x crossref_primary_10_3389_fcell_2021_797005 crossref_primary_10_1186_s40478_025_02025_9 crossref_primary_10_3390_biomedicines9121932 crossref_primary_10_3892_mmr_2025_13432 crossref_primary_10_1016_j_jpain_2022_02_006 crossref_primary_10_1016_j_canlet_2025_217783 crossref_primary_10_1016_j_sjbs_2022_103308 crossref_primary_10_3390_molecules29173994 crossref_primary_10_3390_jpm11040308 crossref_primary_10_1134_S0006350924701161 crossref_primary_10_3390_molecules29020375 crossref_primary_10_1007_s11033_022_07203_9 crossref_primary_10_1016_j_drup_2021_100797 crossref_primary_10_3390_ijms222011197 crossref_primary_10_1016_j_phymed_2025_156709 crossref_primary_10_3389_fcell_2021_773048 crossref_primary_10_3390_cells14171341 crossref_primary_10_1007_s13237_024_00529_8 crossref_primary_10_1038_s12276_022_00864_3 crossref_primary_10_1016_j_clinre_2022_101976 crossref_primary_10_1007_s12033_023_00998_3 crossref_primary_10_1016_j_ejcb_2025_151494 crossref_primary_10_1126_sciadv_adt7450 crossref_primary_10_1016_j_colsurfa_2025_137400 crossref_primary_10_1016_j_canlet_2023_216181 crossref_primary_10_3389_fncel_2022_841544 crossref_primary_10_1016_j_ejphar_2022_175089 crossref_primary_10_1186_s12864_023_09543_7 crossref_primary_10_1186_s12885_025_14041_y crossref_primary_10_3390_app14219658 crossref_primary_10_1007_s12035_024_04041_7 crossref_primary_10_1002_biof_1947 crossref_primary_10_1002_biof_1944 crossref_primary_10_1016_j_biomaterials_2025_123164 crossref_primary_10_1134_S0022093023020096 crossref_primary_10_3390_cancers15164106 crossref_primary_10_1038_s41389_024_00537_y crossref_primary_10_3390_cancers14061538 crossref_primary_10_1002_iub_2514 crossref_primary_10_1002_cdt3_120 crossref_primary_10_1073_pnas_2423066122 crossref_primary_10_1186_s12967_024_04870_z crossref_primary_10_1016_j_cbi_2022_109843 crossref_primary_10_1016_j_ijrobp_2021_06_021 crossref_primary_10_1016_j_envpol_2021_116495 crossref_primary_10_3390_molecules28237797 crossref_primary_10_3390_cancers14102486 crossref_primary_10_3390_ijms26104570 crossref_primary_10_1080_14756366_2023_2230388 crossref_primary_10_1111_apha_14154 crossref_primary_10_3389_fphar_2022_791272 crossref_primary_10_1016_j_bbcan_2025_189358 crossref_primary_10_1186_s43046_025_00261_7 crossref_primary_10_1007_s00277_025_06571_z crossref_primary_10_3390_cancers13163949 crossref_primary_10_1016_j_compbiolchem_2025_108425 crossref_primary_10_3390_molecules26164951 crossref_primary_10_1016_j_heliyon_2025_e41897 crossref_primary_10_3390_cancers14081882 crossref_primary_10_1016_j_intimp_2024_112004 crossref_primary_10_1016_j_ejphar_2024_177222 crossref_primary_10_1097_CM9_0000000000002404 crossref_primary_10_1007_s12013_025_01829_9 crossref_primary_10_1002_cbin_12277 crossref_primary_10_1177_09603271231188493 crossref_primary_10_1007_s00210_025_04405_3 crossref_primary_10_3390_cancers14194562 crossref_primary_10_1186_s12935_024_03279_4 crossref_primary_10_1016_j_foodchem_2024_140540 crossref_primary_10_1002_mco2_187 crossref_primary_10_3389_fimmu_2023_1233652 crossref_primary_10_3389_fmicb_2025_1632425 crossref_primary_10_1080_00365521_2024_2315317 crossref_primary_10_1186_s13058_024_01924_4 crossref_primary_10_1016_j_brainresbull_2022_08_014 crossref_primary_10_1016_j_lfs_2021_119984 crossref_primary_10_1002_jat_4398 crossref_primary_10_1002_ptr_8131 crossref_primary_10_1016_j_bbrep_2025_102046 crossref_primary_10_1186_s13062_023_00368_8 crossref_primary_10_3390_ijms252011201 crossref_primary_10_1016_j_prmcm_2024_100386 crossref_primary_10_1080_07391102_2021_2016487 crossref_primary_10_3390_molecules29153531 crossref_primary_10_1002_med_21955 crossref_primary_10_1016_j_gene_2022_146942 crossref_primary_10_1038_s41540_022_00214_z crossref_primary_10_3390_nu14153169 crossref_primary_10_1002_cai2_84 crossref_primary_10_3389_fonc_2021_698023 crossref_primary_10_1002_JLB_2A1220_850RRR crossref_primary_10_1186_s12967_024_05543_7 crossref_primary_10_1016_j_carbpol_2024_121897 crossref_primary_10_1186_s12885_022_09684_0 crossref_primary_10_3390_ijms24043065 crossref_primary_10_3892_br_2025_1938 crossref_primary_10_3390_life12111890 crossref_primary_10_3390_ijms26083813 crossref_primary_10_1016_j_bbcan_2025_189324 crossref_primary_10_1186_s12645_023_00204_8 crossref_primary_10_1007_s00775_023_02030_0 crossref_primary_10_3390_cells11182859 crossref_primary_10_1016_j_bmc_2025_118094 crossref_primary_10_1016_j_phrs_2022_106456 crossref_primary_10_3390_ijms26051869 crossref_primary_10_1007_s11060_025_05194_8 crossref_primary_10_1016_j_molstruc_2022_133454 crossref_primary_10_1111_cbdd_14034 crossref_primary_10_1007_s12032_025_02904_0 crossref_primary_10_1016_j_ccr_2025_217119 crossref_primary_10_1016_j_archger_2024_105484 crossref_primary_10_3389_fphar_2023_1235285 crossref_primary_10_3390_cancers14153786 crossref_primary_10_3390_cancers13184675 crossref_primary_10_1007_s10637_023_01360_9 crossref_primary_10_3390_molecules30061201 crossref_primary_10_1016_j_ejmech_2025_117910 crossref_primary_10_1016_j_intimp_2025_114629 crossref_primary_10_1038_s41598_025_07642_x crossref_primary_10_1038_s41598_021_99073_7 crossref_primary_10_1186_s40001_023_01216_1 crossref_primary_10_1007_s10456_024_09965_1 crossref_primary_10_2174_0115748928367900250116074925 crossref_primary_10_1016_j_carbpol_2024_122645 crossref_primary_10_1016_j_phymed_2023_155052 crossref_primary_10_3390_cancers16081500 crossref_primary_10_1016_j_bbcan_2024_189100 crossref_primary_10_1038_s41598_024_58882_2 crossref_primary_10_1371_journal_pone_0279752 crossref_primary_10_3390_ijms22052608 crossref_primary_10_1002_1878_0261_70093 crossref_primary_10_1186_s12967_023_04617_2 crossref_primary_10_3390_molecules26226932 crossref_primary_10_1002_ptr_8346 crossref_primary_10_3390_pharmaceutics15082130 crossref_primary_10_3390_cells13030240 crossref_primary_10_1002_jbm_a_37985 crossref_primary_10_3389_fimmu_2021_762564 crossref_primary_10_1007_s12032_023_02274_5 crossref_primary_10_1016_j_prp_2023_154852 crossref_primary_10_2147_BCTT_S316667 crossref_primary_10_1186_s12951_025_03539_z crossref_primary_10_1016_j_humgen_2023_201151 crossref_primary_10_1016_j_leukres_2024_107548 crossref_primary_10_1038_s41419_024_06434_x crossref_primary_10_1016_j_biopha_2021_112309 crossref_primary_10_1016_j_ejphar_2025_177432 crossref_primary_10_20517_cdr_2025_69 crossref_primary_10_3390_life11111247 crossref_primary_10_1016_j_prp_2025_156231 crossref_primary_10_1007_s12032_023_02130_6 crossref_primary_10_2174_0109298673325229240928040758 crossref_primary_10_1007_s11604_023_01446_7 crossref_primary_10_1186_s12964_023_01182_5 crossref_primary_10_1002_cnr2_1942 crossref_primary_10_1016_j_apsb_2024_04_034 crossref_primary_10_1089_dna_2025_0074 crossref_primary_10_3390_ijerph19042064 crossref_primary_10_1016_j_neures_2022_06_003 crossref_primary_10_1186_s12974_023_02824_8 crossref_primary_10_1038_s41419_023_05869_y crossref_primary_10_3390_ijms232012290 crossref_primary_10_3389_fphar_2021_710304 crossref_primary_10_1016_j_biomaterials_2024_122634 crossref_primary_10_1038_s41419_024_06916_y crossref_primary_10_3389_fnmol_2022_984529 crossref_primary_10_1007_s12032_024_02536_w crossref_primary_10_1038_s41419_023_06193_1 crossref_primary_10_1097_MD_0000000000035306 crossref_primary_10_1016_j_neuroscience_2025_02_007 crossref_primary_10_1007_s11033_024_10057_y crossref_primary_10_1016_j_jddst_2022_103845 crossref_primary_10_1016_j_bbcan_2025_189401 crossref_primary_10_3389_fimmu_2025_1621585 crossref_primary_10_1021_acs_jmedchem_5c00783 crossref_primary_10_3390_polym15071703 crossref_primary_10_1038_s41419_024_07155_x crossref_primary_10_3390_cancers13153867 crossref_primary_10_1038_s41467_025_59010_y crossref_primary_10_1016_j_jnutbio_2024_109708 crossref_primary_10_1038_s41417_024_00762_y crossref_primary_10_1155_2021_6880473 crossref_primary_10_3389_fonc_2025_1524182 crossref_primary_10_1016_j_jbi_2024_104762 crossref_primary_10_3389_fonc_2022_908031 crossref_primary_10_1002_cam4_5768 crossref_primary_10_3390_ijms25052911 crossref_primary_10_1080_01443615_2024_2361435 crossref_primary_10_1016_j_biopha_2024_117327 crossref_primary_10_1016_j_canlet_2023_216479 crossref_primary_10_3389_fcell_2024_1431423 crossref_primary_10_1016_j_ccell_2023_04_017 crossref_primary_10_1016_j_bbcan_2024_189216 crossref_primary_10_3389_fphar_2024_1464626 crossref_primary_10_3390_cancers13153757 crossref_primary_10_1016_j_heliyon_2024_e35721 crossref_primary_10_1002_anie_202116722 crossref_primary_10_20517_cdr_2025_95 crossref_primary_10_3390_pharmaceutics14112414 crossref_primary_10_1002_cbf_3668 crossref_primary_10_3390_cancers14194966 crossref_primary_10_3390_ijms222413512 crossref_primary_10_1155_2022_7687154 crossref_primary_10_3390_jox14020036 crossref_primary_10_3389_fimmu_2024_1512349 crossref_primary_10_1038_s41416_023_02140_1 crossref_primary_10_3389_fonc_2023_1279822 crossref_primary_10_1002_adtp_202300309 crossref_primary_10_1002_SMMD_20220013 crossref_primary_10_3390_ph17101399 crossref_primary_10_1016_j_ejmech_2025_117641 crossref_primary_10_1111_jcmm_16560 crossref_primary_10_1186_s12935_023_03042_1 crossref_primary_10_1016_j_cellsig_2022_110350 crossref_primary_10_1007_s00432_025_06244_4 crossref_primary_10_1080_13543776_2024_2338100 crossref_primary_10_3390_ijms26157523 crossref_primary_10_1038_s41698_023_00460_2 crossref_primary_10_3390_pharmaceutics14030590 crossref_primary_10_1016_j_canlet_2021_09_005 crossref_primary_10_1016_j_chembiol_2022_11_005 crossref_primary_10_1007_s12975_023_01178_w crossref_primary_10_1063_5_0186042 crossref_primary_10_1016_j_ijbiomac_2024_130173 crossref_primary_10_1007_s10522_025_10188_0 crossref_primary_10_3389_fncel_2023_1298508 crossref_primary_10_1002_jcb_30433 crossref_primary_10_1177_09731296241286282 crossref_primary_10_1016_j_molstruc_2023_137379 crossref_primary_10_3389_fcell_2021_760705 crossref_primary_10_3389_fonc_2022_903830 crossref_primary_10_1016_j_cej_2025_164470 crossref_primary_10_1016_j_cellsig_2023_110881 crossref_primary_10_1016_j_heliyon_2024_e39229 crossref_primary_10_1093_biolre_ioaf111 crossref_primary_10_1039_D1RA05095H crossref_primary_10_1007_s12032_023_02263_8 crossref_primary_10_1016_j_jbiotec_2024_06_015 crossref_primary_10_3390_cancers13174363 crossref_primary_10_1016_j_ejphar_2025_177564 crossref_primary_10_3892_ol_2022_13388 crossref_primary_10_1016_j_bbcan_2023_189001 crossref_primary_10_3390_ph14111132 crossref_primary_10_1016_j_apsb_2025_07_025 crossref_primary_10_1186_s12935_024_03420_3 crossref_primary_10_1002_mc_23878 crossref_primary_10_1002_advs_202404937 crossref_primary_10_1016_j_ecoenv_2024_116372 crossref_primary_10_1016_j_mcp_2024_101961 crossref_primary_10_1172_JCI186135 crossref_primary_10_2147_CMAR_S457221 crossref_primary_10_1016_j_intimp_2025_114656 crossref_primary_10_1007_s12032_024_02469_4 crossref_primary_10_1021_acsptsci_5c00170 crossref_primary_10_1186_s12906_022_03727_6 crossref_primary_10_3390_cancers16244222 crossref_primary_10_1007_s10522_023_10050_1 crossref_primary_10_1007_s11060_024_04831_y crossref_primary_10_3390_cancers15205103 crossref_primary_10_1002_tox_23952 crossref_primary_10_1016_j_apsb_2022_09_021 crossref_primary_10_1080_14728222_2022_2083957 crossref_primary_10_1186_s12964_022_00840_4 crossref_primary_10_1002_adhm_202302012 crossref_primary_10_1039_D4RA02222J crossref_primary_10_3389_fcell_2024_1442193 crossref_primary_10_1038_s41388_024_03030_3 crossref_primary_10_1002_advs_202306230 crossref_primary_10_1002_ptr_7305 crossref_primary_10_3389_fphar_2025_1516583 crossref_primary_10_3390_ijms222312731 crossref_primary_10_1080_08982104_2021_2001499 crossref_primary_10_1016_j_bmc_2022_116922 crossref_primary_10_1016_j_bbamcr_2023_119573 crossref_primary_10_1038_s41467_023_44572_6 crossref_primary_10_1016_j_ijbiomac_2024_134981 crossref_primary_10_1007_s12033_023_00707_0 crossref_primary_10_2174_0109298673261625230924114406 crossref_primary_10_1016_j_ijbiomac_2025_143739 crossref_primary_10_3390_cancers16234003 crossref_primary_10_3390_cancers16142544 crossref_primary_10_1186_s12967_023_04651_0 crossref_primary_10_3390_ijms26146935 crossref_primary_10_1016_j_phrs_2025_107958 crossref_primary_10_1186_s13046_023_02823_w crossref_primary_10_1007_s11033_024_09895_7 crossref_primary_10_1080_87559129_2022_2141776 crossref_primary_10_1002_ange_202116722 crossref_primary_10_1016_j_bbagen_2023_130486 crossref_primary_10_3389_fphar_2021_653306 crossref_primary_10_1038_s41598_025_86911_1 crossref_primary_10_1080_15592294_2023_2298058 crossref_primary_10_3390_scipharm90010012 crossref_primary_10_3390_ijms24119256 crossref_primary_10_1016_j_heliyon_2024_e35901 crossref_primary_10_3390_cells11040650 crossref_primary_10_3390_ph16060906 crossref_primary_10_1080_09553002_2021_1928786 crossref_primary_10_1186_s12885_022_09499_z crossref_primary_10_1186_s13020_024_00903_3 crossref_primary_10_1038_s41571_025_01059_1 crossref_primary_10_3390_ijms222111376 crossref_primary_10_1016_j_lfs_2022_120443 crossref_primary_10_1016_j_ctarc_2025_100881 crossref_primary_10_1016_j_lfs_2022_120442 crossref_primary_10_1097_MD_0000000000038536 crossref_primary_10_3390_cancers13143427 crossref_primary_10_1080_14756366_2023_2237209 crossref_primary_10_1158_0008_5472_CAN_21_2964 crossref_primary_10_3390_foods13010163 crossref_primary_10_1016_j_bioactmat_2025_05_029 crossref_primary_10_1016_j_imu_2023_101320 crossref_primary_10_1097_CM9_0000000000003640 crossref_primary_10_1002_pep2_24371 crossref_primary_10_3390_cancers13092024 crossref_primary_10_3390_biomedicines12071610 crossref_primary_10_3390_cancers15215297 crossref_primary_10_3390_ijms25021010 crossref_primary_10_3390_ijms25137003 crossref_primary_10_1016_j_bbrc_2025_151827 crossref_primary_10_1016_j_pharmthera_2024_108755 crossref_primary_10_1007_s13167_021_00242_5 crossref_primary_10_1007_s13346_025_01859_z crossref_primary_10_1007_s12672_025_02471_w crossref_primary_10_1016_j_bbrc_2023_08_014 crossref_primary_10_3389_fphar_2022_895738 crossref_primary_10_3389_fphar_2022_946210 crossref_primary_10_1007_s00210_025_04077_z crossref_primary_10_26508_lsa_202201732 crossref_primary_10_3389_fonc_2022_876556 crossref_primary_10_1002_jemt_70049 crossref_primary_10_1007_s12013_024_01296_8 crossref_primary_10_1016_j_tice_2024_102599 crossref_primary_10_1039_D2CC02343A crossref_primary_10_3389_fphar_2022_1108776 crossref_primary_10_3389_fimmu_2024_1480596 crossref_primary_10_3390_ph15101199 crossref_primary_10_1186_s13041_025_01206_w crossref_primary_10_1016_j_yexcr_2022_113266 crossref_primary_10_3390_v13081488 crossref_primary_10_1016_j_tranon_2021_101193 crossref_primary_10_1007_s00210_022_02354_9 crossref_primary_10_1007_s10565_021_09632_x crossref_primary_10_1016_j_biopha_2025_118103 crossref_primary_10_1186_s12935_025_03658_5 crossref_primary_10_3390_app14219687 crossref_primary_10_1038_s41467_025_56711_2 crossref_primary_10_1186_s12920_024_01865_z crossref_primary_10_3390_cancers17101610 crossref_primary_10_1111_jcmm_18352 crossref_primary_10_1177_10849785251376173 crossref_primary_10_1080_02713683_2021_1925697 crossref_primary_10_2174_0109298673288542240327112351 crossref_primary_10_1186_s12951_021_01086_x crossref_primary_10_3390_cancers16050885 crossref_primary_10_1093_jimmun_vkae037 crossref_primary_10_3390_ijms26104814 crossref_primary_10_1177_03946320231223005 crossref_primary_10_1007_s12032_025_02966_0 crossref_primary_10_1016_j_molstruc_2023_135358 crossref_primary_10_1186_s13046_021_02050_1 crossref_primary_10_3390_biomedicines10092060 crossref_primary_10_3390_ijms26094365 crossref_primary_10_1007_s10555_023_10134_x crossref_primary_10_3390_ijms25158252 crossref_primary_10_1021_acs_jproteome_4c00919 crossref_primary_10_3390_ijms24021357 crossref_primary_10_1016_j_jpba_2024_115979 crossref_primary_10_1016_j_aquaculture_2023_740382 crossref_primary_10_3233_ADR_210061 crossref_primary_10_1016_j_ejmcr_2025_100283 crossref_primary_10_3389_fmed_2025_1569732 crossref_primary_10_3390_cancers16213572 crossref_primary_10_1177_14703203241265218 crossref_primary_10_1016_j_jep_2024_118885 crossref_primary_10_1039_D5MD00021A crossref_primary_10_1038_s41420_023_01319_y crossref_primary_10_1038_s41419_021_04133_5 crossref_primary_10_1016_j_ijantimicag_2025_107595 crossref_primary_10_1002_advs_202408106 crossref_primary_10_1111_febs_16639 crossref_primary_10_1016_j_hermed_2024_100882 crossref_primary_10_1111_bph_70102 crossref_primary_10_3892_ijo_2025_5741 crossref_primary_10_1089_ars_2021_0183 crossref_primary_10_1002_cti2_70011 crossref_primary_10_1016_j_acthis_2022_151874 crossref_primary_10_1111_cpr_13608 crossref_primary_10_1186_s12885_025_14081_4 crossref_primary_10_3389_fendo_2022_927329 crossref_primary_10_3390_ijms252312840 crossref_primary_10_1016_j_bbrc_2021_12_095 crossref_primary_10_3389_fcell_2021_784983 crossref_primary_10_1016_j_ctarc_2022_100512 crossref_primary_10_3390_genes12071094 crossref_primary_10_1016_j_intimp_2021_107830 crossref_primary_10_1016_j_jbc_2023_105344 crossref_primary_10_2147_DDDT_S297013 crossref_primary_10_1016_j_lfs_2022_121320 crossref_primary_10_3390_ijms25137428 crossref_primary_10_1177_1934578X251330748 crossref_primary_10_1007_s11033_024_09669_1 crossref_primary_10_1038_s41598_025_86096_7 crossref_primary_10_1007_s00520_025_09344_6 crossref_primary_10_1007_s13402_024_00982_2 crossref_primary_10_1186_s12957_025_03732_2 crossref_primary_10_3390_jpm12081277 crossref_primary_10_1016_j_abb_2023_109551 crossref_primary_10_1016_j_apsb_2022_10_002 crossref_primary_10_3390_ijms241813949 crossref_primary_10_1186_s12964_024_01878_2 crossref_primary_10_3390_molecules26195904 crossref_primary_10_1016_j_bioorg_2024_107212 crossref_primary_10_1111_cas_16278 crossref_primary_10_3389_fonc_2021_671382 crossref_primary_10_1007_s11033_025_10474_7 crossref_primary_10_3389_fimmu_2025_1511029 crossref_primary_10_1016_j_semcancer_2021_08_011 crossref_primary_10_1016_j_brainresbull_2025_111189 crossref_primary_10_1155_2022_7858925 crossref_primary_10_1186_s12957_025_03658_9 crossref_primary_10_1007_s11011_023_01177_8 crossref_primary_10_1016_j_jhip_2025_05_001 crossref_primary_10_1186_s12943_023_01827_6 crossref_primary_10_1016_j_tranon_2023_101814 crossref_primary_10_1093_carcin_bgac088 crossref_primary_10_2174_0109298673308301240821052742 crossref_primary_10_1016_j_drup_2023_101004 crossref_primary_10_1097_CAD_0000000000001591 crossref_primary_10_1002_mco2_665 crossref_primary_10_1080_21655979_2021_1936831 crossref_primary_10_1016_j_freeradbiomed_2022_08_015 crossref_primary_10_1002_mco2_782 crossref_primary_10_3892_ijmm_2024_5456 crossref_primary_10_3390_cells10061426 crossref_primary_10_2478_sjecr_2021_0037 crossref_primary_10_1016_j_device_2024_100420 crossref_primary_10_3390_biom13091306 crossref_primary_10_1007_s10863_023_09986_3 crossref_primary_10_1007_s13225_023_00528_1 crossref_primary_10_3892_etm_2023_11897 crossref_primary_10_32604_oncologie_2022_022121 crossref_primary_10_1016_j_jstrokecerebrovasdis_2021_106295 crossref_primary_10_3389_fonc_2022_813852 crossref_primary_10_1186_s12575_023_00228_9 crossref_primary_10_3390_molecules26237390 crossref_primary_10_1016_j_gene_2025_149352 crossref_primary_10_3390_life13020264 crossref_primary_10_1002_mnfr_202100738 crossref_primary_10_1007_s13346_024_01653_3 crossref_primary_10_3390_ijms26157434 crossref_primary_10_4103_jcrt_jcrt_641_21 crossref_primary_10_1007_s11547_024_01890_z crossref_primary_10_3390_ph18040494 crossref_primary_10_1007_s00210_023_02757_2 crossref_primary_10_1186_s12935_023_03010_9 crossref_primary_10_3390_cells10061411 crossref_primary_10_1007_s12032_021_01606_7 crossref_primary_10_3390_molecules27217466 crossref_primary_10_1038_s41598_023_29644_3 crossref_primary_10_1186_s12967_023_04841_w crossref_primary_10_3389_fphar_2024_1331648 crossref_primary_10_1016_j_bioorg_2025_108639 crossref_primary_10_1080_21655979_2021_1964156 crossref_primary_10_3390_cancers16132478 crossref_primary_10_3389_fphar_2022_768556 crossref_primary_10_1080_1062936X_2023_2181392 crossref_primary_10_3390_ijms23115892 crossref_primary_10_3389_fnmol_2022_910543 crossref_primary_10_1007_s00432_022_04236_2 crossref_primary_10_34133_bmr_0095 crossref_primary_10_1186_s13046_022_02443_w crossref_primary_10_1007_s10495_024_01967_0 crossref_primary_10_1016_j_ajg_2023_02_004 crossref_primary_10_1371_journal_pone_0323979 crossref_primary_10_3390_ph16020302 crossref_primary_10_1016_j_bioorg_2024_107498 crossref_primary_10_1016_j_cca_2025_120242 crossref_primary_10_1016_j_jhazmat_2025_138458 crossref_primary_10_1016_j_bbcan_2023_188987 crossref_primary_10_1007_s10495_022_01750_z crossref_primary_10_1002_slct_202501703 crossref_primary_10_1186_s43556_022_00110_2 crossref_primary_10_3390_ijms24021417 crossref_primary_10_3390_ijms252111638 crossref_primary_10_1007_s12032_023_02138_y crossref_primary_10_1186_s13578_023_01185_2
Cites_doi	10.1016/j.celrep.2015.07.016 10.12703/P7-13 10.1161/HYPERTENSIONAHA.118.12378 10.1016/j.jgr.2019.07.001 10.1016/S1368-7646(02)00003-1 10.1038/aps.2011.92 10.1038/cdd.2011.121 10.1007/s11064-017-2297-6 10.1016/j.phymed.2019.152885 10.18632/oncotarget.15832 10.1158/1535-7163.MCT-17-0927 10.1111/bph.12367 10.1016/j.semcancer.2019.06.019 10.1038/s41419-018-0849-6 10.1186/1477-7819-11-120 10.1136/thoraxjnl-2015-207429 10.1159/000496040 10.1038/cddis.2015.363 10.1016/j.lungcan.2012.07.005 10.1038/emboj.2013.133 10.1016/j.lfs.2019.116548 10.1254/jphs.10244FP 10.1038/ncomms4480 10.2147/OTT.S152818 10.1038/cdd.2017.161 10.1038/cdd.2013.153 10.1016/j.lfs.2018.10.050 10.1074/jbc.A116.312044 10.1007/s13277-014-2497-5 10.3892/mmr.2017.7822 10.1142/S0192415X15500834 10.1186/1476-4598-12-44 10.1158/2159-8290.CD-15-0460 10.1186/s13045-018-0621-5 10.1002/path.1725 10.1111/jcmm.14200 10.1016/j.molcel.2018.03.018 10.4103/0973-1482.203599 10.1080/13543784.2019.1676726 10.1016/j.ctrv.2013.08.006 10.1016/j.cell.2019.01.017 10.1111/febs.13188 10.2174/1381612825666191112142943 10.1016/j.ygyno.2015.02.003 10.1158/1535-7163.MCT-19-0261 10.1038/sj.leu.2404523 10.1016/j.cellsig.2011.03.017 10.3389/fonc.2020.00393 10.1038/sj.onc.1209201 10.3892/or.2016.5154 10.1038/cdd.2017.41 10.2174/18715206113139990119 10.3390/ijms21093233 10.1080/01635581.2019.1578387 10.1016/j.ejphar.2014.07.054 10.3390/biom9120759 10.1097/CAD.0000000000000561 10.1073/pnas.1501441112 10.1042/BSR20181693 10.1016/j.taap.2018.10.025 10.4103/0973-1482.157323 10.1159/000495499 10.1038/s41419-019-1591-4 10.1111/apm.12398 10.1016/S0092-8674(01)00330-0 10.1158/0008-5472.CAN-04-4547 10.1158/0008-5472.CAN-16-2874 10.1002/jcp.29333 10.1186/s13046-017-0639-5 10.3390/cells7080107 10.3390/ijms20194917 10.1002/med.21549 10.3892/ijo.2014.2297 10.1016/0005-2736(76)90160-7 10.1159/000490142 10.1038/s41379-019-0357-y 10.1007/s11095-019-2695-3 10.1111/jnc.14899 10.1016/j.bulcan.2015.09.011 10.3389/fphar.2018.01545 10.1007/s11912-019-0846-7 10.1002/cncr.32677 10.1016/j.lfs.2019.116730 10.1016/j.cbi.2018.09.001 10.1016/j.cmet.2007.10.002 10.1016/j.cmet.2015.10.005 10.1038/srep44541 10.1016/j.devcel.2016.02.012 10.1016/j.abb.2017.08.009 10.1002/ijc.29850 10.1016/j.ejpb.2019.10.007 10.1016/j.jnutbio.2018.09.022 10.1002/ptr.6355 10.1158/0008-5472.CAN-17-0366 10.1042/BSR20181711 10.3390/molecules24162881 10.3892/or.2017.5892 10.3390/ijms20174242 10.2217/nnm-2017-0184 10.1016/j.semcancer.2019.07.022 10.1158/1078-0432.CCR-18-2293 10.1038/s41416-020-0783-0 10.1002/jcp.25706 10.1038/aps.2016.121 10.1002/ijc.24772 10.3390/cells8050431 10.3390/cells8101271 10.3892/mmr.2017.6189 10.1038/bjc.2012.40 10.1039/C5MB00101C 10.1016/j.semcancer.2019.05.012 10.2147/OTT.S153814 10.1038/nrc706 10.3390/cancers11050656 10.1038/s41417-018-0031-4 10.1016/j.cbi.2019.03.032 10.1016/j.bbrc.2016.03.141 10.1186/s12864-017-4027-5 10.3892/or.2013.2520 10.1016/j.semcancer.2008.11.010 10.1158/1535-7163.MCT-09-0191 10.1002/cncr.31921 10.1007/s11033-019-04929-x 10.1007/s11010-013-1853-x 10.1080/09513590.2017.1411474
ContentType	Journal Article
Copyright	The Author(s) 2020
Copyright_xml	– notice: The Author(s) 2020
DBID	C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM
DOI	10.1038/s41419-020-02998-6
DatabaseName	Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles)
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Biology
EISSN	2041-4889
ExternalDocumentID	PMC7515865 32973135 10_1038_s41419_020_02998_6
Genre	Research Support, Non-U.S. Gov't Journal Article Review
GrantInformation_xml	– fundername: Natural Science Foundation of Beijing Municipality (Beijing Natural Science Foundation) grantid: 7202111; 7202111; 7202111; 7202111; 7202111; 7202111; 7202111; 7202111; 7202111 funderid: https://doi.org/10.13039/501100004826 – fundername: ; grantid: 7202111; 7202111; 7202111; 7202111; 7202111; 7202111; 7202111; 7202111; 7202111
GroupedDBID	--- 0R~ 3V. 53G 5VS 70F 7X7 88A 88I 8FE 8FH 8FI 8FJ AAJSJ ABUWG ACGFS ACSMW ADBBV AENEX AFKRA AJTQC ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI C6C CCPQU DIK DWQXO E3Z EBLON EBS EMOBN FRP FYUFA GNUQQ GROUPED_DOAJ HCIFZ HMCUK HYE HZ~ KQ8 LK8 M0L M2P M48 M7P M~E NAO O5R O5S O9- OK1 PIMPY PQQKQ PROAC RNT RPM SNYQT TR2 UKHRP W2D AASML AAYXX AFFHD CITATION PHGZM PHGZT PQGLB CGR CUY CVF ECM EIF NPM 7X8 5PM
ID	FETCH-LOGICAL-c512t-c3113ab0795f265fd879a0decab369634e4071b9bd963c1c8e63325d3ca026b13
ISICitedReferencesCount	654
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000576279100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	2041-4889
IngestDate	Tue Nov 04 01:33:17 EST 2025 Sun Nov 09 11:55:50 EST 2025 Thu Jan 02 22:55:41 EST 2025 Sat Nov 29 05:57:13 EST 2025 Tue Nov 18 22:00:44 EST 2025 Fri Feb 21 02:37:18 EST 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	9
Language	English
License	Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel	OpenURL
MergedId	FETCHMERGED-LOGICAL-c512t-c3113ab0795f265fd879a0decab369634e4071b9bd963c1c8e63325d3ca026b13
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23
OpenAccessLink	http://dx.doi.org/10.1038/s41419-020-02998-6
PMID	32973135
PQID	2446668196
PQPubID	23479
ParticipantIDs	pubmedcentral_primary_oai_pubmedcentral_nih_gov_7515865 proquest_miscellaneous_2446668196 pubmed_primary_32973135 crossref_citationtrail_10_1038_s41419_020_02998_6 crossref_primary_10_1038_s41419_020_02998_6 springer_journals_10_1038_s41419_020_02998_6
PublicationCentury	2000
PublicationDate	2020-09-24
PublicationDateYYYYMMDD	2020-09-24
PublicationDate_xml	– month: 09 year: 2020 text: 2020-09-24 day: 24
PublicationDecade	2020
PublicationPlace	London
PublicationPlace_xml	– name: London – name: England
PublicationTitle	Cell death & disease
PublicationTitleAbbrev	Cell Death Dis
PublicationTitleAlternate	Cell Death Dis
PublicationYear	2020
Publisher	Nature Publishing Group UK
Publisher_xml	– name: Nature Publishing Group UK
References	Ellis, Ma (CR13) 2019; 21 Ni, Yi (CR69) 2017; 16 Robey, Hay (CR124) 2009; 19 Juliano, Ling (CR97) 1976; 455 Sochalska, Tuzlak, Egle, Villunger (CR36) 2015; 282 Jin, Xiong, Cen (CR19) 2017; 28 CR38 Millis (CR17) 2019; 125 Knoechel, Aster (CR127) 2015; 22 Wang (CR18) 2014; 386 Xu (CR59) 2018; 17 Li (CR114) 2019; 71 Rocha Gda, Oliveira, Kaplan, Gattass (CR20) 2014; 741 Adams, Cory (CR41) 2018; 25 Li (CR58) 2019; 23 Fei, Chi, Weng (CR47) 2013; 11 Wu, Chen, Wu, Wang, Guo (CR26) 2018; 37 Ersahin, Tuncbag, Cetin-Atalay (CR129) 2015; 11 Zhao (CR94) 2018; 9 Tazzari (CR30) 2007; 21 Yeh (CR122) 2020; 33 Levy (CR98) 2019; 145 Li (CR107) 2019; 305 Ediriweera, Tennekoon, Samarakoon (CR10) 2019; 59 Feng (CR117) 2016; 36 Pollen (CR132) 2019; 176 Sharma (CR1) 2017; 12 Usman (CR62) 2018; 9 Cai, Li, Jiang, Zhao, Yang (CR106) 2019; 33 Liu (CR134) 2019; 18 Huang, Wu, Mei, Wu (CR57) 2013; 32 Shariati, Meric-Bernstam (CR32) 2019; 28 Roundhill, Burchill (CR108) 2012; 106 Li (CR116) 2019; 231 Rittler (CR12) 2019; 20 Choi (CR40) 2019; 43 Huber, Weis (CR89) 2001; 105 Dong (CR137) 2020; 10 Asselin, Mills, Tsang (CR55) 2001; 61 Fraser (CR48) 2003; 63 Volkmann, Marassi, Newmeyer, Hanein (CR39) 2014; 21 CR54 CR135 Kumar (CR75) 2019; 73 Rubinstein (CR14) 2020; 126 Yao, Wei, Lu (CR112) 2016; 473 Kaewpiboon (CR103) 2014; 44 Cheng (CR49) 2002; 5 Qian (CR53) 2018; 14 Brown, Toker (CR65) 2015; 7 Chen, Liu, Yuan, Qiao (CR70) 2018; 15 Kaufmann, Strasser, Jost (CR51) 2012; 19 Kyrochristos, Ziogas, Roukos (CR27) 2019; 39 Tong, Pelling (CR72) 2013; 13 Zhao (CR87) 2017; 7 Hosios (CR126) 2016; 36 DeBerardinis, Lum, Hatzivassiliou, Thompson (CR5) 2008; 7 Wu (CR9) 2019; 10 Oh, Kim, Nam, Shin (CR28) 2017; 636 CR68 Chen (CR64) 2017; 8 Feng (CR130) 2018; 34 CR61 Yang (CR3) 2018; 11 Meng (CR136) 2015; 43 Tasioudi (CR21) 2015; 123 Zhang (CR6) 2017; 15 Zhang, Wu, Tashiro, Onodera, Ikejima (CR37) 2011; 32 Kahana (CR50) 2011; 23 Garcia-Mayea, Mir, Masson, Paciucci, LLeonart (CR2) 2020; 60 Liu, Wang, Chen, Cheng, Cheng (CR35) 2018; 11 Lin (CR119) 2017; 38 Patel, Macaulay, Woodgett (CR84) 2011; 6 Zhu (CR128) 2019; 233 Marzagalli (CR133) 2019; 59 Mercer (CR79) 2016; 71 Xie, Tang, Zhou, Gao, Zhang (CR102) 2013; 30 Lopes-Rodrigues (CR123) 2017; 7 Garcia-Regalado, Vargas, Garcia-Carranca, Arechaga-Ocampo, Gonzalez-De la Rosa (CR44) 2013; 12 Li (CR42) 2019; 2019 Yasuda (CR63) 2011; 115 To, Tomlinson (CR115) 2013; 170 Tripathi (CR109) 2017; 77 Yue, Qin (CR81) 2019; 26 Fischer, Frei, Moura, Stahel, Felley-Bosco (CR34) 2012; 78 Geng (CR45) 2017; 42 Kuznetsov, Tang, Ivshina (CR25) 2017; 18 Li (CR110) 2018; 296 Chen (CR8) 2018; 47 Dutton, Reynolds, Dawson, Young, Murray (CR66) 2005; 205 Zeng (CR82) 2018; 51 House (CR22) 2017; 77 Hu (CR67) 2015; 6 Shafran (CR120) 2005; 65 CR125 Lee (CR131) 2018; 70 Heavey, O’Byrne, Gately (CR43) 2014; 40 Ghandadi (CR60) 2019; 25 Zhang (CR31) 2018; 215 Yuan (CR104) 2020; 122 Guo (CR96) 2019; 2019 Rahmani (CR11) 2020; 235 Dan (CR56) 2016; 291 Gottesman, Fojo, Bates (CR4) 2002; 2 Zhu (CR24) 2016; 138 Abdul-Ghani (CR111) 2006; 25 De Marco (CR15) 2013; 8 Gao, Xia, Zhang, Yang, Kong (CR113) 2019; 58 Sui (CR23) 2014; 14 Li, Qian, Li, Zhu (CR83) 2019; 18 Liu (CR77) 2015; 5 von Achenbach (CR86) 2020; 153 CR93 Wang, Nao, Zhang, He (CR46) 2014; 35 CR92 Wang (CR85) 2017; 232 CR90 Ranjbar (CR95) 2019; 362 Balaji (CR52) 2018; 11 Soltani, Torki, Ghahfarokhi, Jami, Ghatrehsamani (CR7) 2019; 46 Deng (CR73) 2017; 38 Brotelle, Bay (CR71) 2016; 103 Shahbazi (CR105) 2018; 14 Chen (CR118) 2010; 126 Annageldiyev (CR138) 2020; 10 Harding (CR16) 2019; 25 Yu, Zheng, Chan, Wu (CR80) 2017; 7 Hashimoto (CR99) 2019; 36 Wang (CR91) 2015; 112 CR100 Wang, Lin, Li (CR121) 2019; 41 Dai (CR76) 2018; 51 Yamamoto (CR33) 2014; 5 Muthusamy, Gunaseelan, Prasad (CR101) 2019; 63 Mabuchi, Kuroda, Takahashi, Sasano (CR74) 2015; 137 Lampada (CR29) 2017; 24 Zhou (CR88) 2009; 8 Yang, Murashige, Humphrey, James (CR78) 2015; 12 JH Lee (2998_CR131) 2018; 70 VA Kuznetsov (2998_CR25) 2017; 18 J Jin (2998_CR19) 2017; 28 B Fei (2998_CR47) 2013; 11 P Liu (2998_CR77) 2015; 5 Y Garcia-Mayea (2998_CR2) 2020; 60 MK Ediriweera (2998_CR10) 2019; 59 2998_CR90 A Lampada (2998_CR29) 2017; 24 Z Ni (2998_CR69) 2017; 16 YC Yeh (2998_CR122) 2020; 33 C Feng (2998_CR130) 2018; 34 RJ DeBerardinis (2998_CR5) 2008; 7 Z Li (2998_CR83) 2019; 18 Y Meng (2998_CR136) 2015; 43 SZ Millis (2998_CR17) 2019; 125 KE Tasioudi (2998_CR21) 2015; 123 JM Adams (2998_CR41) 2018; 25 C von Achenbach (2998_CR86) 2020; 153 Q Zhou (2998_CR88) 2009; 8 T Ersahin (2998_CR129) 2015; 11 L Deng (2998_CR73) 2017; 38 X Tong (2998_CR72) 2013; 13 C Yang (2998_CR3) 2018; 11 Z Chen (2998_CR118) 2010; 126 T Yamamoto (2998_CR33) 2014; 5 S Ranjbar (2998_CR95) 2019; 362 X Zhang (2998_CR6) 2017; 15 D Rittler (2998_CR12) 2019; 20 SC Tripathi (2998_CR109) 2017; 77 S Oh (2998_CR28) 2017; 636 G Yang (2998_CR78) 2015; 12 PF Mercer (2998_CR79) 2016; 71 E Asselin (2998_CR55) 2001; 61 P Chen (2998_CR64) 2017; 8 2998_CR100 H Qian (2998_CR53) 2018; 14 Q Guo (2998_CR96) 2019; 2019 X Li (2998_CR58) 2019; 23 H Li (2998_CR116) 2019; 231 A Garcia-Regalado (2998_CR44) 2013; 12 X Huang (2998_CR57) 2013; 32 C De Marco (2998_CR15) 2013; 8 KK Brown (2998_CR65) 2015; 7 AA Pollen (2998_CR132) 2019; 176 Y Chen (2998_CR8) 2018; 47 H Ellis (2998_CR13) 2019; 21 T Kaufmann (2998_CR51) 2012; 19 H Cai (2998_CR106) 2019; 33 M Marzagalli (2998_CR133) 2019; 59 2998_CR92 T Brotelle (2998_CR71) 2016; 103 ZA Zhao (2998_CR87) 2017; 7 2998_CR93 N Hashimoto (2998_CR99) 2019; 36 S Balaji (2998_CR52) 2018; 11 EA Roundhill (2998_CR108) 2012; 106 S Xu (2998_CR59) 2018; 17 G Rocha Gda (2998_CR20) 2014; 741 M Fraser (2998_CR48) 2003; 63 R Abdul-Ghani (2998_CR111) 2006; 25 A Dutton (2998_CR66) 2005; 205 F Rahmani (2998_CR11) 2020; 235 MM Rubinstein (2998_CR14) 2020; 126 L Wang (2998_CR121) 2019; 41 M Sochalska (2998_CR36) 2015; 282 X Yu (2998_CR80) 2017; 7 J Lin (2998_CR119) 2017; 38 L Liu (2998_CR134) 2019; 18 S Patel (2998_CR84) 2011; 6 Y Dai (2998_CR76) 2018; 51 T Yasuda (2998_CR63) 2011; 115 H Sui (2998_CR23) 2014; 14 E Choi (2998_CR40) 2019; 43 2998_CR125 W Chen (2998_CR70) 2018; 15 L Zeng (2998_CR82) 2018; 51 R Shahbazi (2998_CR105) 2018; 14 CD House (2998_CR22) 2017; 77 V Kumar (2998_CR75) 2019; 73 HX Geng (2998_CR45) 2017; 42 S Feng (2998_CR117) 2016; 36 X Zhang (2998_CR31) 2018; 215 B Liu (2998_CR35) 2018; 11 2998_CR38 N Volkmann (2998_CR39) 2014; 21 AM Hosios (2998_CR126) 2016; 36 M Ghandadi (2998_CR60) 2019; 25 B Fischer (2998_CR34) 2012; 78 2998_CR135 RL Juliano (2998_CR97) 1976; 455 C Annageldiyev (2998_CR138) 2020; 10 PL Tazzari (2998_CR30) 2007; 21 Y Li (2998_CR114) 2019; 71 B Knoechel (2998_CR127) 2015; 22 Y Hu (2998_CR67) 2015; 6 M Shariati (2998_CR32) 2019; 28 J Yao (2998_CR112) 2016; 473 MM Gottesman (2998_CR4) 2002; 2 ID Kyrochristos (2998_CR27) 2019; 39 A Shafran (2998_CR120) 2005; 65 RB Robey (2998_CR124) 2009; 19 C Kaewpiboon (2998_CR103) 2014; 44 S Li (2998_CR110) 2018; 296 HC Dan (2998_CR56) 2016; 291 2998_CR68 V Lopes-Rodrigues (2998_CR123) 2017; 7 G Muthusamy (2998_CR101) 2019; 63 W Wang (2998_CR85) 2017; 232 W Zhu (2998_CR128) 2019; 233 JQ Cheng (2998_CR49) 2002; 5 A Soltani (2998_CR7) 2019; 46 RQ Zhao (2998_CR94) 2018; 9 2998_CR61 S Mabuchi (2998_CR74) 2015; 137 HL Gao (2998_CR113) 2019; 58 X Xie (2998_CR102) 2013; 30 DM Wu (2998_CR9) 2019; 10 G Wang (2998_CR91) 2015; 112 A Sharma (2998_CR1) 2017; 12 AH Huber (2998_CR89) 2001; 105 KK To (2998_CR115) 2013; 170 SJ Wu (2998_CR26) 2018; 37 S Heavey (2998_CR43) 2014; 40 DD Zhu (2998_CR24) 2016; 138 JH Wang (2998_CR46) 2014; 35 C Dong (2998_CR137) 2020; 10 2998_CR54 P Li (2998_CR42) 2019; 2019 JJ Harding (2998_CR16) 2019; 25 Z Yuan (2998_CR104) 2020; 122 YH Zhang (2998_CR37) 2011; 32 S Kahana (2998_CR50) 2011; 23 D Yue (2998_CR81) 2019; 26 MW Usman (2998_CR62) 2018; 9 ES Levy (2998_CR98) 2019; 145 DG Wang (2998_CR18) 2014; 386 Y Li (2998_CR107) 2019; 305
References_xml	– volume: 12 start-page: 937 year: 2015 end-page: 943 ident: CR78 article-title: A positive feedback loop between Akt and mTORC2 via SIN1 phosphorylation publication-title: Cell Rep. doi: 10.1016/j.celrep.2015.07.016 – volume: 7 start-page: 13 year: 2015 ident: CR65 article-title: The phosphoinositide 3-kinase pathway and therapy resistance in cancer publication-title: F1000prime Rep. doi: 10.12703/P7-13 – volume: 8 start-page: 1684 year: 2009 end-page: 1691 ident: CR88 article-title: Luteolin inhibits invasion of prostate cancer PC3 cells through E-cadherin publication-title: Mol. Cancer Ther. – ident: CR68 – volume: 7 start-page: 11 year: 2008 end-page: 20 ident: CR5 article-title: The biology of cancer: metabolic reprogramming fuels cell growth and proliferation publication-title: Cell Metab. – volume: 28 start-page: 1141 year: 2017 end-page: 1149 ident: CR19 article-title: Bcl-2 and Bcl-xL mediate resistance to receptor tyrosine kinase-targeted therapy in lung and gastric cancer publication-title: Anti-cancer Drugs – volume: 73 start-page: 630 year: 2019 end-page: 639 ident: CR75 article-title: Therapeutic suppression of mTOR (mammalian target of rapamycin) signaling prevents and reverses salt-induced hypertension and kidney injury in dahl salt-sensitive rats publication-title: Hypertension doi: 10.1161/HYPERTENSIONAHA.118.12378 – volume: 44 start-page: 1233 year: 2014 end-page: 1242 ident: CR103 article-title: Feroniellin A-induced autophagy causes apoptosis in multidrug-resistant human A549 lung cancer cells publication-title: Int. J. Oncol. – volume: 7 year: 2017 ident: CR123 article-title: Identification of the metabolic alterations associated with the multidrug resistant phenotype in cancer and their intercellular transfer mediated by extracellular vesicles publication-title: Sci. Rep. – volume: 7 start-page: 1769 year: 2017 end-page: 1778 ident: CR80 article-title: Modulation of chemoresponsiveness to platinum-based agents by microRNAs in cancer publication-title: Am. J. Cancer Res. – ident: CR135 – volume: 33 start-page: 1683 year: 2019 end-page: 1688 ident: CR106 article-title: Costunolide enhances sensitivity of K562/ADR chronic myeloid leukemia cells to doxorubicin through PI3K/Akt pathway publication-title: Phytother. Res. – volume: 11 start-page: 1946 year: 2015 end-page: 1954 ident: CR129 article-title: The PI3K/AKT/mTOR interactive pathway publication-title: Mol. Biosyst. – ident: CR54 – volume: 43 start-page: 692 year: 2019 end-page: 698 ident: CR40 article-title: AKT1-targeted proapoptotic activity of compound K in human breast cancer cells publication-title: J. Ginseng Res. doi: 10.1016/j.jgr.2019.07.001 – volume: 5 start-page: 131 year: 2002 end-page: 146 ident: CR49 article-title: Role of X-linked inhibitor of apoptosis protein in chemoresistance in ovarian cancer: possible involvement of the phosphoinositide-3 kinase/Akt pathway publication-title: Drug Resist. Updates doi: 10.1016/S1368-7646(02)00003-1 – volume: 15 start-page: 3883 year: 2018 end-page: 3889 ident: CR70 article-title: HSPA12B overexpression induces cisplatin resistance in non-small-cell lung cancer by regulating the PI3K/Akt/NF-kappaB signaling pathway publication-title: Oncol. Lett. – volume: 32 start-page: 1266 year: 2011 end-page: 1275 ident: CR37 article-title: Reactive oxygen species contribute to oridonin-induced apoptosis and autophagy in human cervical carcinoma HeLa cells publication-title: Acta Pharmacol. Sin. doi: 10.1038/aps.2011.92 – volume: 19 start-page: 42 year: 2012 end-page: 50 ident: CR51 article-title: Fas death receptor signalling: roles of Bid and XIAP publication-title: Cell Death Differ. doi: 10.1038/cdd.2011.121 – volume: 42 start-page: 2841 year: 2017 end-page: 2849 ident: CR45 article-title: 14,15-EET suppresses neuronal apoptosis in ischemia-reperfusion through the mitochondrial pathway publication-title: Neurochem. Res. doi: 10.1007/s11064-017-2297-6 – volume: 58 start-page: 152885 year: 2019 ident: CR113 article-title: Vielanin P enhances the cytotoxicity of doxorubicin via the inhibition of PI3K/Nrf2-stimulated MRP1 expression in MCF-7 and K562 DOX-resistant cell lines publication-title: Phytomedicine doi: 10.1016/j.phymed.2019.152885 – volume: 126 start-page: 841 year: 2010 end-page: 851 ident: CR118 article-title: Suppression of ABCG2 inhibits cancer cell proliferation publication-title: Int. J. Cancer – volume: 20 start-page: 4917 year: 2019 ident: CR12 article-title: The antitumor effect of lipophilic bisphosphonate BPH1222 in melanoma models: the role of the PI3K/Akt pathway and the small G protein Rheb publication-title: Int. J. Mol. Sci. – volume: 106 start-page: 1224 year: 2012 end-page: 1233 ident: CR108 article-title: Detection and characterisation of multi-drug resistance protein 1 (MRP-1) in human mitochondria publication-title: Br. J. Cancer – volume: 8 start-page: 27471 year: 2017 end-page: 27480 ident: CR64 article-title: Luteolin inhibits cell proliferation and induces cell apoptosis via down-regulation of mitochondrial membrane potential in esophageal carcinoma cells EC1 and KYSE450 publication-title: Oncotarget doi: 10.18632/oncotarget.15832 – ident: CR92 – volume: 17 start-page: 1291 year: 2018 end-page: 1302 ident: CR59 article-title: Metformin suppresses tumor progression by inactivating stromal fibroblasts in ovarian cancer publication-title: Mol. Cancer Ther. doi: 10.1158/1535-7163.MCT-17-0927 – volume: 41 start-page: 1678 year: 2019 end-page: 1690 ident: CR121 article-title: The PI3K/AKT signaling pathway regulates ABCG2 expression and confers resistance to chemotherapy in human multiple myeloma publication-title: Oncol. Rep. – volume: 170 start-page: 1137 year: 2013 end-page: 1151 ident: CR115 article-title: Targeting the ABCG2-overexpressing multidrug resistant (MDR) cancer cells by PPARgamma agonists publication-title: Br. J. Pharmacol. doi: 10.1111/bph.12367 – volume: 59 start-page: 221 year: 2019 end-page: 235 ident: CR133 article-title: Cellular and molecular biology of cancer stem cells in melanoma: Possible therapeutic implications publication-title: Semin. Cancer Biol. doi: 10.1016/j.semcancer.2019.06.019 – volume: 24 start-page: 1045 year: 2017 end-page: 1062 ident: CR29 article-title: mTORC1-independent autophagy regulates receptor tyrosine kinase phosphorylation in colorectal cancer cells via an mTORC2-mediated mechanism publication-title: Cell Death Differ. – volume: 9 start-page: 809 year: 2018 ident: CR62 article-title: Macrophages confer resistance to PI3K inhibitor GDC-0941 in breast cancer through the activation of NF-kappaB signaling publication-title: Cell Death Dis. doi: 10.1038/s41419-018-0849-6 – volume: 15 start-page: 1869 year: 2017 end-page: 1876 ident: CR6 article-title: Glycometabolic adaptation mediates the insensitivity of drug-resistant K562/ADM leukaemia cells to adriamycin via the AKT-mTOR/c-Myc signalling pathway publication-title: Mol. Med. Rep. – volume: 61 start-page: 1862 year: 2001 end-page: 1868 ident: CR55 article-title: XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells publication-title: Cancer Res. – volume: 455 start-page: 152 year: 1976 end-page: 162 ident: CR97 article-title: A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants publication-title: Biochim. Biophys. Acta – ident: CR100 – volume: 10 start-page: 263 year: 2020 end-page: 274 ident: CR137 article-title: Econazole nitrate reversed the resistance of breast cancer cells to Adriamycin through inhibiting the PI3K/AKT signaling pathway publication-title: Am. J. Cancer Res. – volume: 47 start-page: 981 year: 2018 end-page: 993 ident: CR8 article-title: The critical role of PTEN/PI3K/AKT signaling pathway in shikonin-induced apoptosis and proliferation inhibition of chronic myeloid leukemia publication-title: Cell. Physiol. Biochem.l. – volume: 11 year: 2013 ident: CR47 article-title: Hydroxycamptothecin induces apoptosis and inhibits tumor growth in colon cancer by the downregulation of survivin and XIAP expression publication-title: World J. Surg. Oncol. doi: 10.1186/1477-7819-11-120 – volume: 71 start-page: 701 year: 2016 end-page: 711 ident: CR79 article-title: Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF publication-title: Thorax doi: 10.1136/thoraxjnl-2015-207429 – volume: 14 year: 2014 ident: CR23 article-title: Zuo Jin Wan reverses P-gp-mediated drug-resistance by inhibiting activation of the PI3K/Akt/NF-kappaB pathway publication-title: BMC Complement. Altern. Med. – volume: 18 year: 2017 ident: CR25 article-title: Identification of common oncogenic and early developmental pathways in the ovarian carcinomas controlling by distinct prognostically significant microRNA subsets publication-title: BMC Genom. – volume: 112 start-page: 2853 year: 2015 end-page: 2858 ident: CR91 article-title: HDAC inhibition prevents white matter injury by modulating microglia/macrophage polarization through the GSK3beta/PTEN/Akt axis publication-title: Proc. Natl Acad. Sci. USA – volume: 51 start-page: 2872 year: 2018 end-page: 2886 ident: CR76 article-title: lncRNA MEG3 suppresses the tumorigenesis of hemangioma by sponging miR-494 and regulating PTEN/ PI3K/AKT pathway publication-title: Cell. Physiol. Biochem. doi: 10.1159/000496040 – volume: 26 start-page: 1 year: 2019 end-page: 10 ident: CR81 article-title: miR-182 regulates trastuzumab resistance by targeting MET in breast cancer cells publication-title: Cancer Gene Ther. – volume: 305 start-page: 98 year: 2019 end-page: 104 ident: CR107 article-title: Guajadial reverses multidrug resistance by inhibiting ABC transporter expression and suppressing the PI3K/Akt pathway in drug-resistant breast cancer cells publication-title: Chem.-Biol. Interact. – volume: 233 start-page: 116730 year: 2019 ident: CR128 article-title: Dihydroartemisinin suppresses glycolysis of LNCaP cells by inhibiting PI3K/AKT pathway and downregulating HIF-1alpha expression publication-title: Life Sci. – volume: 12 start-page: 2137 year: 2017 end-page: 2148 ident: CR1 article-title: Chemoresistance in cancer cells: exosomes as potential regulators of therapeutic tumor heterogeneity publication-title: Nanomedicine – volume: 25 start-page: 2116 year: 2019 end-page: 2126 ident: CR16 article-title: Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies publication-title: Clin. Cancer Res. – volume: 296 start-page: 45 year: 2018 end-page: 56 ident: CR110 article-title: The roles of breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance-associated proteins (MRPs/ABCCs) in the excretion of cycloicaritin-3-O-glucoronide in UGT1A1-overexpressing HeLa cells publication-title: Chem.-Biol. Interact. – volume: 59 start-page: 147 year: 2019 end-page: 160 ident: CR10 article-title: Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: biological and therapeutic significance publication-title: Semin. Cancer Biol. – volume: 6 year: 2015 ident: CR67 article-title: Effects of PI3K inhibitor NVP-BKM120 on overcoming drug resistance and eliminating cancer stem cells in human breast cancer cells publication-title: Cell Death Dis. doi: 10.1038/cddis.2015.363 – volume: 60 start-page: 166 year: 2020 end-page: 180 ident: CR2 article-title: Insights into new mechanisms and models of cancer stem cell multidrug resistance publication-title: Semin. Cancer Biol. – volume: 232 start-page: 2829 year: 2017 end-page: 2840 ident: CR85 article-title: NOR1 suppresses cancer stem-like cells properties of tumor cells via the inhibition of the AKT-GSK-3beta-Wnt/beta-catenin-ALDH1A1 signal circuit publication-title: J. Cell. Physiol. – volume: 71 start-page: 1007 year: 2019 end-page: 1018 ident: CR114 article-title: Involvement of the PI3K/Akt/Nrf2 signaling pathway in resveratrol-mediated reversal of drug resistance in HL-60/ADR cells publication-title: Nutr. Cancer – volume: 78 start-page: 23 year: 2012 end-page: 29 ident: CR34 article-title: Inhibition of phosphoinositide-3 kinase pathway down regulates ABCG2 function and sensitizes malignant pleural mesothelioma to chemotherapy publication-title: Lung Cancer doi: 10.1016/j.lungcan.2012.07.005 – volume: 21 year: 2019 ident: CR13 article-title: PI3K inhibitors in breast cancer therapy publication-title: Curr. Oncol. Rep. – volume: 37 start-page: 18 year: 2018 ident: CR26 article-title: MicroRNA-150 enhances radiosensitivity by inhibiting the AKT pathway in NK/T cell lymphoma publication-title: J. Exp. Clin. Cancer Res. – volume: 13 start-page: 971 year: 2013 end-page: 978 ident: CR72 article-title: Targeting the PI3K/Akt/mTOR axis by apigenin for cancer prevention publication-title: Anti-cancer Agents Med. Chem. – volume: 38 start-page: 2293 year: 2017 end-page: 2300 ident: CR119 article-title: Scutellaria barbata D. Don inhibits 5-fluorouracil resistance in colorectal cancer by regulating PI3K/AKT pathway publication-title: Oncol. Rep. – volume: 32 start-page: 2204 year: 2013 end-page: 2216 ident: CR57 article-title: XIAP inhibits autophagy via XIAP-Mdm2-p53 signalling publication-title: EMBO J. doi: 10.1038/emboj.2013.133 – volume: 231 start-page: 116548 year: 2019 ident: CR116 article-title: Comparison of LC–MS/MS-based targeted proteomics and conventional analytical methods for monitoring breast cancer resistance protein expression publication-title: Life Sci. doi: 10.1016/j.lfs.2019.116548 – ident: CR38 – volume: 153 start-page: 510 year: 2020 end-page: 524 ident: CR86 article-title: Synergistic growth inhibition mediated by dual PI3K/mTOR pathway targeting and genetic or direct pharmacological AKT inhibition in human glioblastoma models publication-title: J. Neurochem. – volume: 741 start-page: 140 year: 2014 end-page: 149 ident: CR20 article-title: 3beta-acetyl tormentic acid reverts MRP1/ABCC1 mediated cancer resistance through modulation of intracellular levels of GSH and inhibition of GST activity publication-title: Eur. J. Pharmacol. – volume: 22 start-page: 759 year: 2015 end-page: 760 ident: CR127 article-title: Metabolic mechanisms of drug resistance in leukemia publication-title: Cell Metab. – volume: 115 start-page: 509 year: 2011 end-page: 515 ident: CR63 article-title: Hyaluronan inhibits Akt, leading to nuclear factor-kappaB down-regulation in lipopolysaccharide-stimulated U937 macrophages publication-title: J. Pharmacol. Sci. doi: 10.1254/jphs.10244FP – volume: 5 year: 2014 ident: CR33 article-title: Reduced methylation of PFKFB3 in cancer cells shunts glucose towards the pentose phosphate pathway publication-title: Nat. Commun. doi: 10.1038/ncomms4480 – volume: 145 start-page: 76 year: 2019 end-page: 84 ident: CR98 article-title: Reversible inhibition of efflux transporters by hydrogel microdevices publication-title: Eur. J. Pharm. Biopharm. – volume: 11 start-page: 211 year: 2018 end-page: 220 ident: CR35 article-title: RACKI induces chemotherapy resistance in esophageal carcinoma by upregulating the PI3K/AKT pathway and Bcl-2 expression publication-title: OncoTargets Ther. doi: 10.2147/OTT.S152818 – volume: 25 start-page: 27 year: 2018 end-page: 36 ident: CR41 article-title: The BCL-2 arbiters of apoptosis and their growing role as cancer targets publication-title: Cell Death Differ. doi: 10.1038/cdd.2017.161 – volume: 21 start-page: 206 year: 2014 end-page: 215 ident: CR39 article-title: The rheostat in the membrane: BCL-2 family proteins and apoptosis publication-title: Cell Death Differ. doi: 10.1038/cdd.2013.153 – volume: 19 start-page: 25 year: 2009 end-page: 31 ident: CR124 article-title: Is Akt the “Warburg kinase”?-Akt-energy metabolism interactions and oncogenesis publication-title: Semin. Cancer Biol. – volume: 215 start-page: 1 year: 2018 end-page: 10 ident: CR31 article-title: Targeting glycometabolic reprogramming to restore the sensitivity of leukemia drug-resistant K562/ADM cells to adriamycin publication-title: Life Sci. doi: 10.1016/j.lfs.2018.10.050 – volume: 63 start-page: 7081 year: 2003 end-page: 7088 ident: CR48 article-title: p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells publication-title: Cancer Res. – ident: CR125 – volume: 125 start-page: 1185 year: 2019 end-page: 1199 ident: CR17 article-title: Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities publication-title: Cancer – volume: 291 start-page: 22846 year: 2016 ident: CR56 article-title: Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP) publication-title: J. Biol. Chem. doi: 10.1074/jbc.A116.312044 – volume: 6 year: 2011 ident: CR84 article-title: Tissue-specific analysis of glycogen synthase kinase-3alpha (GSK-3alpha) in glucose metabolism: effect of strain variation publication-title: PLoS ONE – volume: 33 start-page: 391 year: 2020 end-page: 403 ident: CR122 article-title: AKT1 internal tandem duplications and point mutations are the genetic hallmarks of sclerosing pneumocytoma publication-title: Modern Pathol. – ident: CR93 – volume: 235 start-page: 4146 year: 2020 end-page: 4152 ident: CR11 article-title: Role of regulatory miRNAs of the PI3K/AKT/mTOR signaling in the pathogenesis of hepatocellular carcinoma publication-title: J. Cell. Physiol. – volume: 63 start-page: 62 year: 2019 end-page: 71 ident: CR101 article-title: Ferulic acid reverses P-glycoprotein-mediated multidrug resistance via inhibition of PI3K/Akt/NF-kappaB signaling pathway publication-title: J. Nutr. Biochem. – volume: 65 start-page: 8414 year: 2005 end-page: 8422 ident: CR120 article-title: ABCG2 harboring the Gly482 mutation confers high-level resistance to various hydrophilic antifolates publication-title: Cancer Res. – volume: 39 start-page: 1205 year: 2019 end-page: 1227 ident: CR27 article-title: Dynamic genome and transcriptional network-based biomarkers and drugs: precision in breast cancer therapy publication-title: Med. Res. Rev. – volume: 123 start-page: 639 year: 2015 end-page: 647 ident: CR21 article-title: Immunohistochemical and molecular analysis of PI3K/AKT/mTOR pathway in esophageal carcinoma publication-title: Acta Pathol. Microbiol. Immunol. Scand. – volume: 2019 start-page: 4390839 year: 2019 ident: CR96 article-title: Ubenimex reverses MDR in gastric cancer cells by activating caspase-3-mediated apoptosis and suppressing the expression of membrane transport proteins publication-title: BioMed. Res. Int. – ident: CR61 – volume: 35 start-page: 11985 year: 2014 end-page: 11994 ident: CR46 article-title: 20(s)-ginsenoside Rg3 promotes apoptosis in human ovarian cancer HO-8910 cells through PI3K/Akt and XIAP pathways publication-title: Tumour Biol. doi: 10.1007/s13277-014-2497-5 – volume: 16 start-page: 9701 year: 2017 end-page: 9706 ident: CR69 article-title: Oxymatrine induces nasopharyngeal cancer cell death through inhibition of PI3K/AKT and NFkappaB pathways publication-title: Mol. Med. Rep. doi: 10.3892/mmr.2017.7822 – volume: 43 start-page: 1471 year: 2015 end-page: 1486 ident: CR136 article-title: Ursolic acid induces apoptosis of prostate cancer cells via the PI3K/Akt/mTOR pathway publication-title: Am. J. Chin. Med. doi: 10.1142/S0192415X15500834 – volume: 25 start-page: 1743 year: 2006 end-page: 1752 ident: CR111 article-title: The PI3K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1 publication-title: Oncogene – volume: 12 year: 2013 ident: CR44 article-title: Activation of Akt pathway by transcription-independent mechanisms of retinoic acid promotes survival and invasion in lung cancer cells publication-title: Mol. Cancer doi: 10.1186/1476-4598-12-44 – volume: 5 start-page: 1194 year: 2015 end-page: 1209 ident: CR77 article-title: PtdIns(3,4,5)P3-dependent activation of the mTORC2 kinase complex publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-15-0460 – volume: 36 start-page: 540 year: 2016 end-page: 549 ident: CR126 article-title: Amino acids rather than glucose account for the majority of cell mass in proliferating mammalian cells publication-title: Dev. Cell – volume: 11 start-page: 983 year: 2018 end-page: 996 ident: CR3 article-title: Kanglaite reverses multidrug resistance of HCC by inducing apoptosis and cell cycle arrest via PI3K/AKT pathway publication-title: OncoTargets Ther. – volume: 7 year: 2017 ident: CR87 article-title: Adenosine A2A receptor inactivation alleviates early-onset cognitive dysfunction after traumatic brain injury involving an inhibition of tau hyperphosphorylation publication-title: Transl. Psychiatry – volume: 636 start-page: 110 year: 2017 end-page: 122 ident: CR28 article-title: Silencing of Glut1 induces chemoresistance via modulation of Akt/GSK-3beta/beta-catenin/survivin signaling pathway in breast cancer cells publication-title: Arch. Biochem. Biophys. – volume: 11 start-page: 83 year: 2018 ident: CR52 article-title: NF-kappaB signaling and its relevance to the treatment of mantle cell lymphoma publication-title: J. Hematol. Oncol. doi: 10.1186/s13045-018-0621-5 – volume: 126 start-page: 1274 year: 2020 end-page: 1282 ident: CR14 article-title: Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway publication-title: Cancer – volume: 103 start-page: 18 year: 2016 end-page: 29 ident: CR71 article-title: PI3K-AKT-mTOR pathway: description, therapeutic development, resistance, predictive/prognostic biomarkers and therapeutic applications for cancer publication-title: Bull. Cancer – volume: 138 start-page: 1175 year: 2016 end-page: 1185 ident: CR24 article-title: Significance of NF-kappaB activation in immortalization of nasopharyngeal epithelial cells publication-title: Int. J. Cancer – volume: 9 start-page: 1545 year: 2018 ident: CR94 article-title: Y6, an epigallocatechin gallate derivative, reverses ABCG2-mediated mitoxantrone resistance publication-title: Front. Pharmacol. – volume: 205 start-page: 498 year: 2005 end-page: 506 ident: CR66 article-title: Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin’s lymphoma cells through a mechanism involving Akt kinase and mTOR publication-title: J. Pathol. doi: 10.1002/path.1725 – volume: 77 start-page: 4414 year: 2017 end-page: 4425 ident: CR109 article-title: MCAM mediates chemoresistance in small-cell lung cancer via the PI3K/AKT/SOX2 signaling pathway publication-title: Cancer Res. – volume: 46 start-page: 4809 year: 2019 end-page: 4816 ident: CR7 article-title: Targeting the phosphoinositide 3-kinase/AKT pathways by small molecules and natural compounds as a therapeutic approach for breast cancer cells publication-title: Mol. Biol. Rep. – volume: 105 start-page: 391 year: 2001 end-page: 402 ident: CR89 article-title: The structure of the beta-catenin/E-cadherin complex and the molecular basis of diverse ligand recognition by beta-catenin publication-title: Cell – volume: 23 start-page: 2920 year: 2019 end-page: 2932 ident: CR58 article-title: Down-regulated lncRNA SLC25A5-AS1 facilitates cell growth and inhibits apoptosis via miR-19a-3p/PTEN/PI3K/AKT signalling pathway in gastric cancer publication-title: J. Cell. Mol. Med. doi: 10.1111/jcmm.14200 – volume: 51 start-page: 1221 year: 2018 end-page: 1236 ident: CR82 article-title: Long non-coding RNA XLOC_006753 promotes the development of multidrug resistance in gastric cancer cells through the PI3K/AKT/mTOR signaling pathway publication-title: Cell. Physiol. Biochem. – volume: 10 start-page: 349 year: 2019 ident: CR9 article-title: The PAX6-ZEB2 axis promotes metastasis and cisplatin resistance in non-small cell lung cancer through PI3K/AKT signaling publication-title: Cell Death Dis. – volume: 70 start-page: 197 year: 2018 end-page: 210. e197 ident: CR131 article-title: EGFR-phosphorylated platelet isoform of phosphofructokinase 1 promotes PI3K activation publication-title: Mol. Cell doi: 10.1016/j.molcel.2018.03.018 – volume: 14 start-page: 503 year: 2018 end-page: 508 ident: CR105 article-title: Hesperidin inhibits insulin-induced phosphoinositide 3-kinase/Akt activation in human pre-B cell line NALM-6 publication-title: J. Cancer Res. Ther. – volume: 2019 start-page: 9496419 year: 2019 ident: CR42 article-title: Nicotinic agonist inhibits cardiomyocyte apoptosis in CVB3-induced myocarditis via alpha3beta4-nAChR/PI3K/Akt-dependent survivin upregulation publication-title: Oxid. Med. Cell. Longev. – volume: 473 start-page: 867 year: 2016 end-page: 873 ident: CR112 article-title: Chaetominine reduces MRP1-mediated drug resistance via inhibiting PI3K/Akt/Nrf2 signaling pathway in K562/Adr human leukemia cells publication-title: Biochem. Biophys. Res. Commun. – volume: 14 start-page: S648 year: 2018 end-page: S655 ident: CR53 article-title: X-linked inhibitor of apoptosis protein inhibitor Embelin induces apoptosis via PI3K/Akt pathway and inhibits invasion in osteosarcoma cells publication-title: J. Cancer Res. therapeutics doi: 10.4103/0973-1482.203599 – volume: 386 start-page: 143 year: 2014 end-page: 152 ident: CR18 article-title: Anti-tumor activity of the X-linked inhibitor of apoptosis (XIAP) inhibitor embelin in gastric cancer cells publication-title: Mol. Cell. Biochem. – volume: 28 start-page: 977 year: 2019 end-page: 988 ident: CR32 article-title: Targeting AKT for cancer therapy publication-title: Expert Opin. Investig. Drugs doi: 10.1080/13543784.2019.1676726 – volume: 2 start-page: 48 year: 2002 end-page: 58 ident: CR4 article-title: Multidrug resistance in cancer: role of ATP-dependent transporters publication-title: Nat. Rev. Cancer – volume: 40 start-page: 445 year: 2014 end-page: 456 ident: CR43 article-title: Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC publication-title: Cancer Treat. Rev. doi: 10.1016/j.ctrv.2013.08.006 – volume: 36 start-page: 158 year: 2019 ident: CR99 article-title: Metabolome analysis reveals dermal histamine accumulation in murine dermatitis provoked by genetic deletion of P-glycoprotein and breast cancer resistance protein publication-title: Pharm. Res. – volume: 176 start-page: 743 year: 2019 end-page: 756. e717 ident: CR132 article-title: Establishing cerebral organoids as models of human-specific brain evolution publication-title: Cell doi: 10.1016/j.cell.2019.01.017 – volume: 282 start-page: 834 year: 2015 end-page: 849 ident: CR36 article-title: Lessons from gain- and loss-of-function models of pro-survival Bcl2 family proteins: implications for targeted therapy publication-title: FEBS J. doi: 10.1111/febs.13188 – volume: 25 start-page: 4192 year: 2019 end-page: 4207 ident: CR60 article-title: Wnt-beta-catenin signaling pathway, the Achilles’ heels of cancer multidrug resistance publication-title: Curr. Pharm. Des. doi: 10.2174/1381612825666191112142943 – volume: 137 start-page: 173 year: 2015 end-page: 179 ident: CR74 article-title: The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer publication-title: Gynecol. Oncol. doi: 10.1016/j.ygyno.2015.02.003 – volume: 8 year: 2013 ident: CR15 article-title: Multiple genetic alterations within the PI3K pathway are responsible for AKT activation in patients with ovarian carcinoma publication-title: PLoS ONE – volume: 18 start-page: 2457 year: 2019 end-page: 2468 ident: CR134 article-title: Transgelin 2 promotes paclitaxel resistance, migration, and invasion of breast cancer by directly interacting with PTEN and activating PI3K/Akt/GSK-3beta pathway publication-title: Mol. Cancer Ther. doi: 10.1158/1535-7163.MCT-19-0261 – ident: CR90 – volume: 21 start-page: 427 year: 2007 end-page: 438 ident: CR30 article-title: Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts publication-title: Leukemia doi: 10.1038/sj.leu.2404523 – volume: 122 start-page: 1342 year: 2020 end-page: 1353 ident: CR104 article-title: Targeting CD133 reverses drug-resistance via the AKT/NF-kappaB/MDR1 pathway in colorectal cancer publication-title: Br. J. Cancer – volume: 30 start-page: 773 year: 2013 end-page: 782 ident: CR102 article-title: Inhibition of the PI3K/Akt pathway increases the chemosensitivity of gastric cancer to vincristine publication-title: Oncol. Rep. – volume: 23 start-page: 1348 year: 2011 end-page: 1357 ident: CR50 article-title: Proteasome inhibitors sensitize glioma cells and glioma stem cells to TRAIL-induced apoptosis by PKCepsilon-dependent downregulation of AKT and XIAP expressions publication-title: Cell. Signal. doi: 10.1016/j.cellsig.2011.03.017 – volume: 36 start-page: 3207 year: 2016 end-page: 3214 ident: CR117 article-title: Proton pump inhibitor pantoprazole inhibits the proliferation, selfrenewal and chemoresistance of gastric cancer stem cells via the EMT/betacatenin pathways publication-title: Oncol. Rep. – volume: 10 start-page: 393 year: 2020 ident: CR138 article-title: The PI3K/AKT pathway inhibitor ISC-4 induces apoptosis and inhibits growth of leukemia in preclinical models of acute myeloid leukemia publication-title: Front. Oncol. doi: 10.3389/fonc.2020.00393 – volume: 18 start-page: 435 year: 2019 end-page: 442 ident: CR83 article-title: Knockdown of lncRNA-HOTAIR downregulates the drug-resistance of breast cancer cells to doxorubicin via the PI3K/AKT/mTOR signaling pathway publication-title: Exp. Ther. Med. – volume: 34 start-page: 567 year: 2018 end-page: 573 ident: CR130 article-title: SHBG expression is correlated with PI3K/AKT pathway activity in a cellular model of human insulin resistance publication-title: Gynecol. Endocrinol. – volume: 77 start-page: 6927 year: 2017 end-page: 6940 ident: CR22 article-title: NFkappaB promotes ovarian tumorigenesis via classical pathways that support proliferative cancer cells and alternative pathways that support ALDH(+) cancer stem-like cells publication-title: Cancer Res. – volume: 362 start-page: 136 year: 2019 end-page: 149 ident: CR95 article-title: 5-Oxo-hexahydroquinoline derivatives as modulators of P-gp, MRP1 and BCRP transporters to overcome multidrug resistance in cancer cells publication-title: Toxicol. Appl. Pharmacol. – volume: 38 start-page: 382 year: 2017 end-page: 391 ident: CR73 article-title: The PI3K/mTOR dual inhibitor BEZ235 suppresses proliferation and migration and reverses multidrug resistance in acute myeloid leukemia publication-title: Acta Pharmacol. Sin. – volume: 14 year: 2014 ident: 2998_CR23 publication-title: BMC Complement. Altern. Med. – volume: 25 start-page: 1743 year: 2006 ident: 2998_CR111 publication-title: Oncogene doi: 10.1038/sj.onc.1209201 – volume: 36 start-page: 3207 year: 2016 ident: 2998_CR117 publication-title: Oncol. Rep. doi: 10.3892/or.2016.5154 – volume: 205 start-page: 498 year: 2005 ident: 2998_CR66 publication-title: J. Pathol. doi: 10.1002/path.1725 – volume: 40 start-page: 445 year: 2014 ident: 2998_CR43 publication-title: Cancer Treat. Rev. doi: 10.1016/j.ctrv.2013.08.006 – volume: 24 start-page: 1045 year: 2017 ident: 2998_CR29 publication-title: Cell Death Differ. doi: 10.1038/cdd.2017.41 – volume: 13 start-page: 971 year: 2013 ident: 2998_CR72 publication-title: Anti-cancer Agents Med. Chem. doi: 10.2174/18715206113139990119 – volume: 12 start-page: 937 year: 2015 ident: 2998_CR78 publication-title: Cell Rep. doi: 10.1016/j.celrep.2015.07.016 – volume: 73 start-page: 630 year: 2019 ident: 2998_CR75 publication-title: Hypertension doi: 10.1161/HYPERTENSIONAHA.118.12378 – ident: 2998_CR135 doi: 10.3390/ijms21093233 – volume: 25 start-page: 27 year: 2018 ident: 2998_CR41 publication-title: Cell Death Differ. doi: 10.1038/cdd.2017.161 – volume: 7 start-page: 1769 year: 2017 ident: 2998_CR80 publication-title: Am. J. Cancer Res. – volume: 71 start-page: 1007 year: 2019 ident: 2998_CR114 publication-title: Nutr. Cancer doi: 10.1080/01635581.2019.1578387 – volume: 16 start-page: 9701 year: 2017 ident: 2998_CR69 publication-title: Mol. Med. Rep. doi: 10.3892/mmr.2017.7822 – volume: 741 start-page: 140 year: 2014 ident: 2998_CR20 publication-title: Eur. J. Pharmacol. doi: 10.1016/j.ejphar.2014.07.054 – volume: 8 year: 2013 ident: 2998_CR15 publication-title: PLoS ONE – ident: 2998_CR100 doi: 10.3390/biom9120759 – volume: 28 start-page: 1141 year: 2017 ident: 2998_CR19 publication-title: Anti-cancer Drugs doi: 10.1097/CAD.0000000000000561 – volume: 112 start-page: 2853 year: 2015 ident: 2998_CR91 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.1501441112 – ident: 2998_CR92 doi: 10.1042/BSR20181693 – volume: 362 start-page: 136 year: 2019 ident: 2998_CR95 publication-title: Toxicol. Appl. Pharmacol. doi: 10.1016/j.taap.2018.10.025 – volume: 41 start-page: 1678 year: 2019 ident: 2998_CR121 publication-title: Oncol. Rep. – volume: 12 year: 2013 ident: 2998_CR44 publication-title: Mol. Cancer doi: 10.1186/1476-4598-12-44 – volume: 170 start-page: 1137 year: 2013 ident: 2998_CR115 publication-title: Br. J. Pharmacol. doi: 10.1111/bph.12367 – volume: 63 start-page: 7081 year: 2003 ident: 2998_CR48 publication-title: Cancer Res. – volume: 14 start-page: 503 year: 2018 ident: 2998_CR105 publication-title: J. Cancer Res. Ther. doi: 10.4103/0973-1482.157323 – volume: 10 start-page: 393 year: 2020 ident: 2998_CR138 publication-title: Front. Oncol. doi: 10.3389/fonc.2020.00393 – volume: 23 start-page: 2920 year: 2019 ident: 2998_CR58 publication-title: J. Cell. Mol. Med. doi: 10.1111/jcmm.14200 – volume: 51 start-page: 1221 year: 2018 ident: 2998_CR82 publication-title: Cell. Physiol. Biochem. doi: 10.1159/000495499 – volume: 10 start-page: 349 year: 2019 ident: 2998_CR9 publication-title: Cell Death Dis. doi: 10.1038/s41419-019-1591-4 – volume: 78 start-page: 23 year: 2012 ident: 2998_CR34 publication-title: Lung Cancer doi: 10.1016/j.lungcan.2012.07.005 – volume: 14 start-page: S648 year: 2018 ident: 2998_CR53 publication-title: J. Cancer Res. therapeutics doi: 10.4103/0973-1482.203599 – volume: 123 start-page: 639 year: 2015 ident: 2998_CR21 publication-title: Acta Pathol. Microbiol. Immunol. Scand. doi: 10.1111/apm.12398 – volume: 115 start-page: 509 year: 2011 ident: 2998_CR63 publication-title: J. Pharmacol. Sci. doi: 10.1254/jphs.10244FP – volume: 105 start-page: 391 year: 2001 ident: 2998_CR89 publication-title: Cell doi: 10.1016/S0092-8674(01)00330-0 – volume: 2019 start-page: 9496419 year: 2019 ident: 2998_CR42 publication-title: Oxid. Med. Cell. Longev. – volume: 18 start-page: 435 year: 2019 ident: 2998_CR83 publication-title: Exp. Ther. Med. – volume: 65 start-page: 8414 year: 2005 ident: 2998_CR120 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-04-4547 – volume: 77 start-page: 4414 year: 2017 ident: 2998_CR109 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-16-2874 – volume: 235 start-page: 4146 year: 2020 ident: 2998_CR11 publication-title: J. Cell. Physiol. doi: 10.1002/jcp.29333 – volume: 37 start-page: 18 year: 2018 ident: 2998_CR26 publication-title: J. Exp. Clin. Cancer Res. doi: 10.1186/s13046-017-0639-5 – volume: 5 start-page: 131 year: 2002 ident: 2998_CR49 publication-title: Drug Resist. Updates doi: 10.1016/S1368-7646(02)00003-1 – ident: 2998_CR93 doi: 10.3390/cells7080107 – volume: 20 start-page: 4917 year: 2019 ident: 2998_CR12 publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms20194917 – volume: 39 start-page: 1205 year: 2019 ident: 2998_CR27 publication-title: Med. Res. Rev. doi: 10.1002/med.21549 – volume: 44 start-page: 1233 year: 2014 ident: 2998_CR103 publication-title: Int. J. Oncol. doi: 10.3892/ijo.2014.2297 – volume: 7 start-page: 13 year: 2015 ident: 2998_CR65 publication-title: F1000prime Rep. doi: 10.12703/P7-13 – volume: 17 start-page: 1291 year: 2018 ident: 2998_CR59 publication-title: Mol. Cancer Ther. doi: 10.1158/1535-7163.MCT-17-0927 – volume: 11 start-page: 83 year: 2018 ident: 2998_CR52 publication-title: J. Hematol. Oncol. doi: 10.1186/s13045-018-0621-5 – volume: 455 start-page: 152 year: 1976 ident: 2998_CR97 publication-title: Biochim. Biophys. Acta doi: 10.1016/0005-2736(76)90160-7 – volume: 47 start-page: 981 year: 2018 ident: 2998_CR8 publication-title: Cell. Physiol. Biochem.l. doi: 10.1159/000490142 – volume: 58 start-page: 152885 year: 2019 ident: 2998_CR113 publication-title: Phytomedicine doi: 10.1016/j.phymed.2019.152885 – volume: 33 start-page: 391 year: 2020 ident: 2998_CR122 publication-title: Modern Pathol. doi: 10.1038/s41379-019-0357-y – volume: 36 start-page: 158 year: 2019 ident: 2998_CR99 publication-title: Pharm. Res. doi: 10.1007/s11095-019-2695-3 – volume: 153 start-page: 510 year: 2020 ident: 2998_CR86 publication-title: J. Neurochem. doi: 10.1111/jnc.14899 – volume: 103 start-page: 18 year: 2016 ident: 2998_CR71 publication-title: Bull. Cancer doi: 10.1016/j.bulcan.2015.09.011 – volume: 32 start-page: 1266 year: 2011 ident: 2998_CR37 publication-title: Acta Pharmacol. Sin. doi: 10.1038/aps.2011.92 – volume: 231 start-page: 116548 year: 2019 ident: 2998_CR116 publication-title: Life Sci. doi: 10.1016/j.lfs.2019.116548 – volume: 9 start-page: 1545 year: 2018 ident: 2998_CR94 publication-title: Front. Pharmacol. doi: 10.3389/fphar.2018.01545 – volume: 137 start-page: 173 year: 2015 ident: 2998_CR74 publication-title: Gynecol. Oncol. doi: 10.1016/j.ygyno.2015.02.003 – volume: 21 year: 2019 ident: 2998_CR13 publication-title: Curr. Oncol. Rep. doi: 10.1007/s11912-019-0846-7 – volume: 126 start-page: 1274 year: 2020 ident: 2998_CR14 publication-title: Cancer doi: 10.1002/cncr.32677 – volume: 32 start-page: 2204 year: 2013 ident: 2998_CR57 publication-title: EMBO J. doi: 10.1038/emboj.2013.133 – volume: 233 start-page: 116730 year: 2019 ident: 2998_CR128 publication-title: Life Sci. doi: 10.1016/j.lfs.2019.116730 – volume: 296 start-page: 45 year: 2018 ident: 2998_CR110 publication-title: Chem.-Biol. Interact. doi: 10.1016/j.cbi.2018.09.001 – volume: 18 start-page: 2457 year: 2019 ident: 2998_CR134 publication-title: Mol. Cancer Ther. doi: 10.1158/1535-7163.MCT-19-0261 – volume: 7 start-page: 11 year: 2008 ident: 2998_CR5 publication-title: Cell Metab. doi: 10.1016/j.cmet.2007.10.002 – volume: 22 start-page: 759 year: 2015 ident: 2998_CR127 publication-title: Cell Metab. doi: 10.1016/j.cmet.2015.10.005 – volume: 21 start-page: 427 year: 2007 ident: 2998_CR30 publication-title: Leukemia doi: 10.1038/sj.leu.2404523 – volume: 7 year: 2017 ident: 2998_CR123 publication-title: Sci. Rep. doi: 10.1038/srep44541 – volume: 36 start-page: 540 year: 2016 ident: 2998_CR126 publication-title: Dev. Cell doi: 10.1016/j.devcel.2016.02.012 – volume: 25 start-page: 4192 year: 2019 ident: 2998_CR60 publication-title: Curr. Pharm. Des. doi: 10.2174/1381612825666191112142943 – volume: 636 start-page: 110 year: 2017 ident: 2998_CR28 publication-title: Arch. Biochem. Biophys. doi: 10.1016/j.abb.2017.08.009 – volume: 176 start-page: 743 year: 2019 ident: 2998_CR132 publication-title: Cell doi: 10.1016/j.cell.2019.01.017 – volume: 138 start-page: 1175 year: 2016 ident: 2998_CR24 publication-title: Int. J. Cancer doi: 10.1002/ijc.29850 – volume: 145 start-page: 76 year: 2019 ident: 2998_CR98 publication-title: Eur. J. Pharm. Biopharm. doi: 10.1016/j.ejpb.2019.10.007 – volume: 63 start-page: 62 year: 2019 ident: 2998_CR101 publication-title: J. Nutr. Biochem. doi: 10.1016/j.jnutbio.2018.09.022 – volume: 33 start-page: 1683 year: 2019 ident: 2998_CR106 publication-title: Phytother. Res. doi: 10.1002/ptr.6355 – volume: 28 start-page: 977 year: 2019 ident: 2998_CR32 publication-title: Expert Opin. Investig. Drugs doi: 10.1080/13543784.2019.1676726 – volume: 9 start-page: 809 year: 2018 ident: 2998_CR62 publication-title: Cell Death Dis. doi: 10.1038/s41419-018-0849-6 – volume: 70 start-page: 197 year: 2018 ident: 2998_CR131 publication-title: Mol. Cell doi: 10.1016/j.molcel.2018.03.018 – volume: 43 start-page: 692 year: 2019 ident: 2998_CR40 publication-title: J. Ginseng Res. doi: 10.1016/j.jgr.2019.07.001 – volume: 77 start-page: 6927 year: 2017 ident: 2998_CR22 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-17-0366 – volume: 5 year: 2014 ident: 2998_CR33 publication-title: Nat. Commun. doi: 10.1038/ncomms4480 – ident: 2998_CR61 doi: 10.1042/BSR20181711 – volume: 8 start-page: 27471 year: 2017 ident: 2998_CR64 publication-title: Oncotarget doi: 10.18632/oncotarget.15832 – ident: 2998_CR38 doi: 10.3390/molecules24162881 – volume: 38 start-page: 2293 year: 2017 ident: 2998_CR119 publication-title: Oncol. Rep. doi: 10.3892/or.2017.5892 – volume: 23 start-page: 1348 year: 2011 ident: 2998_CR50 publication-title: Cell. Signal. doi: 10.1016/j.cellsig.2011.03.017 – ident: 2998_CR90 doi: 10.3390/ijms20174242 – volume: 12 start-page: 2137 year: 2017 ident: 2998_CR1 publication-title: Nanomedicine doi: 10.2217/nnm-2017-0184 – volume: 60 start-page: 166 year: 2020 ident: 2998_CR2 publication-title: Semin. Cancer Biol. doi: 10.1016/j.semcancer.2019.07.022 – volume: 25 start-page: 2116 year: 2019 ident: 2998_CR16 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-18-2293 – volume: 122 start-page: 1342 year: 2020 ident: 2998_CR104 publication-title: Br. J. Cancer doi: 10.1038/s41416-020-0783-0 – volume: 232 start-page: 2829 year: 2017 ident: 2998_CR85 publication-title: J. Cell. Physiol. doi: 10.1002/jcp.25706 – volume: 35 start-page: 11985 year: 2014 ident: 2998_CR46 publication-title: Tumour Biol. doi: 10.1007/s13277-014-2497-5 – volume: 38 start-page: 382 year: 2017 ident: 2998_CR73 publication-title: Acta Pharmacol. Sin. doi: 10.1038/aps.2016.121 – volume: 59 start-page: 221 year: 2019 ident: 2998_CR133 publication-title: Semin. Cancer Biol. doi: 10.1016/j.semcancer.2019.06.019 – volume: 282 start-page: 834 year: 2015 ident: 2998_CR36 publication-title: FEBS J. doi: 10.1111/febs.13188 – volume: 126 start-page: 841 year: 2010 ident: 2998_CR118 publication-title: Int. J. Cancer doi: 10.1002/ijc.24772 – ident: 2998_CR125 doi: 10.3390/cells8050431 – volume: 42 start-page: 2841 year: 2017 ident: 2998_CR45 publication-title: Neurochem. Res. doi: 10.1007/s11064-017-2297-6 – ident: 2998_CR54 doi: 10.3390/cells8101271 – volume: 51 start-page: 2872 year: 2018 ident: 2998_CR76 publication-title: Cell. Physiol. Biochem. doi: 10.1159/000496040 – volume: 10 start-page: 263 year: 2020 ident: 2998_CR137 publication-title: Am. J. Cancer Res. – volume: 15 start-page: 1869 year: 2017 ident: 2998_CR6 publication-title: Mol. Med. Rep. doi: 10.3892/mmr.2017.6189 – volume: 106 start-page: 1224 year: 2012 ident: 2998_CR108 publication-title: Br. J. Cancer doi: 10.1038/bjc.2012.40 – volume: 11 start-page: 1946 year: 2015 ident: 2998_CR129 publication-title: Mol. Biosyst. doi: 10.1039/C5MB00101C – volume: 59 start-page: 147 year: 2019 ident: 2998_CR10 publication-title: Semin. Cancer Biol. doi: 10.1016/j.semcancer.2019.05.012 – volume: 43 start-page: 1471 year: 2015 ident: 2998_CR136 publication-title: Am. J. Chin. Med. doi: 10.1142/S0192415X15500834 – volume: 11 start-page: 983 year: 2018 ident: 2998_CR3 publication-title: OncoTargets Ther. doi: 10.2147/OTT.S153814 – volume: 7 year: 2017 ident: 2998_CR87 publication-title: Transl. Psychiatry – volume: 2 start-page: 48 year: 2002 ident: 2998_CR4 publication-title: Nat. Rev. Cancer doi: 10.1038/nrc706 – volume: 21 start-page: 206 year: 2014 ident: 2998_CR39 publication-title: Cell Death Differ. doi: 10.1038/cdd.2013.153 – volume: 11 start-page: 211 year: 2018 ident: 2998_CR35 publication-title: OncoTargets Ther. doi: 10.2147/OTT.S152818 – ident: 2998_CR68 doi: 10.3390/cancers11050656 – volume: 26 start-page: 1 year: 2019 ident: 2998_CR81 publication-title: Cancer Gene Ther. doi: 10.1038/s41417-018-0031-4 – volume: 71 start-page: 701 year: 2016 ident: 2998_CR79 publication-title: Thorax doi: 10.1136/thoraxjnl-2015-207429 – volume: 305 start-page: 98 year: 2019 ident: 2998_CR107 publication-title: Chem.-Biol. Interact. doi: 10.1016/j.cbi.2019.03.032 – volume: 473 start-page: 867 year: 2016 ident: 2998_CR112 publication-title: Biochem. Biophys. Res. Commun. doi: 10.1016/j.bbrc.2016.03.141 – volume: 18 year: 2017 ident: 2998_CR25 publication-title: BMC Genom. doi: 10.1186/s12864-017-4027-5 – volume: 30 start-page: 773 year: 2013 ident: 2998_CR102 publication-title: Oncol. Rep. doi: 10.3892/or.2013.2520 – volume: 11 year: 2013 ident: 2998_CR47 publication-title: World J. Surg. Oncol. doi: 10.1186/1477-7819-11-120 – volume: 291 start-page: 22846 year: 2016 ident: 2998_CR56 publication-title: J. Biol. Chem. doi: 10.1074/jbc.A116.312044 – volume: 6 year: 2015 ident: 2998_CR67 publication-title: Cell Death Dis. doi: 10.1038/cddis.2015.363 – volume: 19 start-page: 25 year: 2009 ident: 2998_CR124 publication-title: Semin. Cancer Biol. doi: 10.1016/j.semcancer.2008.11.010 – volume: 8 start-page: 1684 year: 2009 ident: 2998_CR88 publication-title: Mol. Cancer Ther. doi: 10.1158/1535-7163.MCT-09-0191 – volume: 15 start-page: 3883 year: 2018 ident: 2998_CR70 publication-title: Oncol. Lett. – volume: 2019 start-page: 4390839 year: 2019 ident: 2998_CR96 publication-title: BioMed. Res. Int. – volume: 19 start-page: 42 year: 2012 ident: 2998_CR51 publication-title: Cell Death Differ. doi: 10.1038/cdd.2011.121 – volume: 125 start-page: 1185 year: 2019 ident: 2998_CR17 publication-title: Cancer doi: 10.1002/cncr.31921 – volume: 5 start-page: 1194 year: 2015 ident: 2998_CR77 publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-15-0460 – volume: 46 start-page: 4809 year: 2019 ident: 2998_CR7 publication-title: Mol. Biol. Rep. doi: 10.1007/s11033-019-04929-x – volume: 386 start-page: 143 year: 2014 ident: 2998_CR18 publication-title: Mol. Cell. Biochem. doi: 10.1007/s11010-013-1853-x – volume: 61 start-page: 1862 year: 2001 ident: 2998_CR55 publication-title: Cancer Res. – volume: 6 year: 2011 ident: 2998_CR84 publication-title: PLoS ONE – volume: 34 start-page: 567 year: 2018 ident: 2998_CR130 publication-title: Gynecol. Endocrinol. doi: 10.1080/09513590.2017.1411474 – volume: 215 start-page: 1 year: 2018 ident: 2998_CR31 publication-title: Life Sci. doi: 10.1016/j.lfs.2018.10.050
SSID	ssj0000330256
Score	2.6975029
SecondaryResourceType	review_article
Snippet	Multidrug resistance (MDR) is the dominant challenge in the failure of chemotherapy in cancers. Phosphatidylinositol 3-kinase (PI3K) is a lipid kinase that...
SourceID	pubmedcentral proquest pubmed crossref springer
SourceType	Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	797
SubjectTerms	631/67/1059/602 631/67/2327 Antibodies Biochemistry Biomedical and Life Sciences Cell Biology Cell Culture Cell Proliferation Drug Resistance, Multiple - genetics Humans Immunology Life Sciences Neoplasms - drug therapy Neoplasms - genetics Proto-Oncogene Proteins c-akt - metabolism Review Review Article Signal Transduction
Title	PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers
URI	https://link.springer.com/article/10.1038/s41419-020-02998-6 https://www.ncbi.nlm.nih.gov/pubmed/32973135 https://www.proquest.com/docview/2446668196 https://pubmed.ncbi.nlm.nih.gov/PMC7515865
Volume	11
WOSCitedRecordID	wos000576279100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2041-4889 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000330256 issn: 2041-4889 databaseCode: DOA dateStart: 20100101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2041-4889 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000330256 issn: 2041-4889 databaseCode: M~E dateStart: 20100101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 2041-4889 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000330256 issn: 2041-4889 databaseCode: M7P dateStart: 20100101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 2041-4889 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000330256 issn: 2041-4889 databaseCode: 7X7 dateStart: 20100101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 2041-4889 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000330256 issn: 2041-4889 databaseCode: BENPR dateStart: 20100101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Publicly Available Content customDbUrl: eissn: 2041-4889 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000330256 issn: 2041-4889 databaseCode: PIMPY dateStart: 20100101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVPQU databaseName: Science Database customDbUrl: eissn: 2041-4889 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000330256 issn: 2041-4889 databaseCode: M2P dateStart: 20100101 isFulltext: true titleUrlDefault: https://search.proquest.com/sciencejournals providerName: ProQuest
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELfYCmgviK9B-aiMxFuJlsRJHD8CGmLaVkWoSOUpcpxkjQRp1TSs46_nzk7SLzHBAy-n1HHsyPfL9c53viPkrc1SFdp5avnC9sFAcTxLJExYMmeMh8rJAy_VxSb4aBROJiJqQnkrXU6Al2W4Won5f2U1tAGz8ejsP7C7GxQa4BqYDhTYDvSvGB-dsXPMknA-xqSp02t5g7Vk5BC-1iG6a7H4DdbswtwOgBEdUZgu6qshGN6oTOKXjrHmeNG4etpMBrjPl6LOqAGz49u5KGrNr7pYhwwYmQYS5Xp94qzpB9gsr35Ni3Wz8f5n5arY3IoAu1N7Z8w_iRZZru2BRRqaokCdfHU2cCQ2hCU3kbl7QtykbK88x8MDVjiNiwcBg83OsObzH5qDTFffMjlPdlJnt7cOSM_lvgCh14vOLqNv3SaczRjqfM1hKpj3ZH_WI3K_HWdbd9kzSPbjanec61pnGT8kDxpjg743IHlE7mTlY3LPlB-9eUIuEConABTaAIXKikoKQKEIFNoBhQJQaAcUugYKneW0AcpT8vXT6fjjZ6uprmEpUPKWlmKOw2Ric-HnbuDnaciFtNNMyQRrPDIvQ1s_EUkKP5SjwixgzPVTpiTY7YnDjslhOSuz54QmIkgEWOrot_M4V6ACApWZk3ksByWpT5x23WLVpJ7HCijfYx0CwcLYLHsMyx7rZY-DPhl2z8xN4pVbe79p2RGDfESnlyyzWV3FLgYsBKD3Qp9nhj3deC1f-4RvMa7rgLnXt--UxVTnYOdgB4QBPPmuZXHcyIDqltd88cdXeEmO1l_UK3K4XNTZa3JX_VwW1WJADviEaxoOSO_D6Sj6MtC7R0Av3QgpB2rQ_RvnVqwW
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=PI3K%2FAKT+pathway+as+a+key+link+modulates+the+multidrug+resistance+of+cancers&rft.jtitle=Cell+death+%26+disease&rft.au=Liu%2C+Rui&rft.au=Chen%2C+Youwen&rft.au=Liu%2C+Guangzhi&rft.au=Li%2C+Chenxi&rft.date=2020-09-24&rft.eissn=2041-4889&rft.volume=11&rft.issue=9&rft.spage=797&rft_id=info:doi/10.1038%2Fs41419-020-02998-6&rft_id=info%3Apmid%2F32973135&rft.externalDocID=32973135
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2041-4889&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2041-4889&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2041-4889&client=summon